Histology-informed liver diffusion MRI: biophysical model design and

demonstration in cancer immunotherapy

Campus, Vall d'Hebron Institute of Oncology (VHIO), Spain

Francesco Grussu¹*, Kinga Bernatowicz¹, Marco Palombo^{2,3}, Irene Casanova-Salas¹, Ignasi 3 Barba^{1,4}, Sara Simonetti¹, Garazi Serna¹, Athanasios Grigoriou^{1,5}, Anna Voronova^{1,5}, Valezka 4 Garay⁶, Juan Francisco Corral^{7,8}, Marta Vidorreta⁹, Pablo García-Polo García¹⁰, Xavier Merino^{7,8}, 5 Richard Mast^{7,8}, Núria Roson^{7,8}, Manuel Escobar^{7,8}, Maria Vieito¹¹, Rodrigo Toledo¹, Paolo 6 Nuciforo¹, Joaquin Mateo¹¹, Elena Garralda¹¹, Raquel Perez-Lopez^{1*} 7 *Joint corresponding authors. Email: fgrussu@vhio.net (F.G.), rperez@vhio.net (R.P.L.) 8 9 ¹ Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 10 Spain² Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, 11 Cardiff University, Cardiff, United Kingdom ³ School of Computer Science and Informatics, 12 Cardiff University, Cardiff, UK ⁴ University of Vic - Central University of Catalonia (UVic-13 UCC), Vic, Spain ⁵ Department of Biomedicine, Faculty of Medicine and Health Sciences, 14 University of Barcelona, Barcelona, Spain ⁶ PET/MR Unit, CETIR-ASCIRES, Barcelona, Spain 15 ⁷ Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain⁸ Institut de 16 Diagnòstic per la Imatge (IDI), Barcelona, Spain ⁹ Siemens Healthineers, Madrid, Spain ¹⁰ GE 17 HealthCare, Madrid, Spain¹¹ Medical Oncology Service, Vall d'Hebron Barcelona Hospital 18

19 20

1

2

- 20
- 21

22 Abstract

Innovative diffusion Magnetic Resonance Imaging (dMRI) models enable in vivo mapping of 23 biologically meaningful properties such as cell size, potential biomarkers in cancer. However, 24 while cancers frequently spread to the liver, models tailored for liver applications and easy to 25 deploy in the clinic are still sought. We tackle this unmet need by delivering a practical and 26 clinically viable liver dMRI modelling framework. Through direct comparison of candidate dMRI 27 approaches in mouse and cancer patients' data, we select a model of intra-cellular diffusion fitted 28 to highly diffusion-weighted images, as it provides the strongest radiological-histological 29 correlates. We demonstrate the potential application of the proposed model in cancer 30 immunotherapy, stratifying the risk of progression based on baseline cell size and density 31 measurements from dMRI. This result, heretofore unreported and not achievable with standard 32 dMRI indices (e.g., apparent diffusion coefficient), suggests that our approach may become a 33 useful tool for precision imaging in oncology. 34

- 35
- 36

37 Introduction

Routine clinical Magnetic Resonance Imaging (MRI) focusses on visualising macroscopic 38 anatomical features, as presence of tumours. Nonetheless, MRI also offers the possibility of 39 measuring biological properties within each pixel of a three-dimensional (3D) scan – known as 40 *voxel*. This approach, referred to as quantitative MRI (qMRI)¹, involves the acquisition of multiple 41 images, each featuring a different contrast, which are then analysed jointly with a mathematical 42 model. qMRI provides promising metrics, which could become quantitative biomarkers 43 complementing the qualitative assessment by the expert radiologist². Diffusion MRI (dMRI) is a 44 gMRI approach that sensitises the signal to water diffusion with magnetic field gradients^{1,3,4}. Since 45 diffusion in biological tissues is influenced by the microenvironment where diffusion takes place, 46 dMRI ultimately enables the indirect estimation of properties at the micrometric scale⁵, such as 47 the size of cells restricting water^{6,7}. dMRI bridges the gap between macroscopic and microscopic 48 imaging, and has found applications in brain⁵, spinal cord⁸, prostate⁶, breast⁹ imaging and beyond. 49

Innovative dMRI techniques are also urgently needed in abdominal imaging, as in liver MRI^{10,11}. 50 The liver is a frequent site for cancer metastasisation ¹², and liver tumours are common targets for 51 treatment response assessment in oncology. However, current response criteria such as RECIST¹³ 52 have limitations, in that they rely on MRI or computed tomography (CT) merely to measure tumour 53 size, without accounting for changes under therapy at the cellular level. Novel dMRI metrics could 54 enable the non-invasive characterisation of cancer microenvironments, shedding light on the 55 composition of tumours that cannot be biopsied. The new readouts could also provide information 56 on tumour heterogeneity, relevant in the development of treatment resistance^{14,15}, and could better 57 stratify patients eligible for treatments such as immunotherapy¹⁶, given the challenge of predicting 58 which patients can benefit from these innovative drugs¹⁷. This would be a major advancement in 59 oncology, as it may allow for personalised treatment planning, reductions in sample sizes in 60 clinical trials, and ultimately improve patient outcomes¹⁸. 61

62 The most recent biophysical dMRI techniques describe the non-vascular liver tissue signal as the sum of contributions from intra-cellular and extra-cellular water¹⁹⁻²¹. While these models provide 63 promising readouts²², their practical use in real-world settings is made unfeasible by i) the high 64 number of dMRI images (and hence long scan time) required to support model fitting, and by ii) 65 the requirement for specialised dMRI acquisitions²³, beyond default examinations available in the 66 scanner console. In this study we aim to tackle this unmet need by delivering a practical liver dMRI 67 signal model that is truly feasible in hospital settings, i.e., on 1.5T or 3T systems, with scan time 68 that does not exceed 15 minutes, and using vendor-provided dMRI sequences. With this objective 69 in mind, we embraced the latest "histology-informed" dMRI development paradigm, which is 70 based on informing signal model design with co-localised histology. The framework has shown 71 promise in delivering dMRI approaches with unprecedented fidelity to cytoarchitecture^{24,25}, 72 maximising biological specificity²⁶. 73

In this article, we aimed to identify a practical mathematicl model that maximises the agreement 74 of dMRI estimates of metrics such as cell size, to their underlying histological counterparts. We 75 analysed a rich data set of dMRI scans and hematoxylin and eosin (HE)-stained images from 76 excised mouse livers and patients' liver biopsies. We used these data to select the model 77 maximising radiological-histological correlations, corroborating results with computer 78 simulations. Afterwards, we demonstrated the clinical utility of the designed approach in one 79 exemplificatory task, assessing response to immunotherapy in patients suffering from advanced 80 solid tumours - an urgent, unmet need, given the lack of robust predictors of treatment response 81 for this class of drugs¹⁷. In summary, our study delivers a liver dMRI approach that offers metrics 82 with high fidelity to histopathology, and which is feasible in the clinic. The proposed method, 83 based on a single-compartment model of restricted, intra-cellular diffusion, fitted to highly 84 diffusion-weighted (DW) images, identified which patients progress faster from baseline dMRI 85 scans. These results, while exploratory and requiring further confirmation, suggest that our dMRI 86 framework could provide complementary information to standard-of-care imaging, and thus play 87 a key role in oncology research and practice. 88

89

90 **Results**

91 **Overview: data set**

Fig. 1 illustrates the data used in this study. We will refer to data obtained in fixed mouse livers as *preclinical*, while to data obtained in cancer patients as *clinical*.

94

92

93

Preclinical data consists of pulsed gradient spin echo (PGSE) DW MRI scans of seven fixed mouse 95 livers, performed ex vivo on a 9.4T Bruker system. It also includes whole-organ HE-stained 96 sections, obtained at known radiographic position. We studied the livers of mice sacrificed as part 97 of xenograft model development in prostate cancer. Six had been implanted with biopsies of 98 prostate cancer patients, while one had not had any implantation. While the livers from the 99 100 implanted mice did not grow any tumours, they feature a variety of pathologies, with three unique histopathological phenotypes (Fig. S1). The liver from the mouse with no implantation features 101 normal liver structures, and we will refer to it as Control. Of the six implanted cases, two also 102 show normal liver tissue, with normal representation of all hepatic structures. We will refer to 103 these cases as *Pat_{NA1}* and *Pat_{NA2}* (patient biopsy implantation, but normal appearing). Another case 104 exhibits generalised necrosis and diffuse acute and chronic inflammation surrounding necrotic 105 areas, with presence of occluded thrombotic vessels. This specimen will be identified as Patnec 106 (patient biopsy implantation, with necrosis). Finally, three specimens feature an immature, 107 lymphoproliferative process, with various degrees of infiltration of small, lymphoid, atypical cells 108 109 with abundant mitosis, which infiltrate portal vessels and sinusoidal capillaries, but without

producing tumours. These will be referred to as *Patinf1* to *Patinf3* (patient biopsy implantation, with lymphoid cell infiltration).

112

We obtained clinical data on cancer patients suffering from advanced solid tumours, participating 113 in an ongoing imaging study at the Barcelona Vall d'Hebron Institute of Oncology (VHIO, Spain). 114 The study involves the acquisition of MRI data, alongside clinical and biological information, in 115 patients eligible for a phase I immunotherapy trial. We included data from 33 patients with liver 116 malignancies (mean/std of age: 62.91/12.34 year; 16 male, 17 female). dMRI was based on 117 diffusion-weighted (DW) echo planar imaging (EPI) scans performed on a 1.5T Siemens Avanto 118 system (Twice-Refocussed Spin Echo (TRSE) DW-EPI) and on a 3T GE SIGNA Pioneer system 119 (PGSE DW-EPI). We also obtained digitised HE-stained biopsies from one of the liver tumours. 120 Biopsies were available for 18 patients, and were collected after dMRI, but before 121 immunotherapy. Clinical outcome (progression-free survival (PFS)) was available for 30 patients, 122 who effectively entered the immunotherapy trial. 123

124

We used dMRI-histology data to design the dMRI signal model (N = 25) and dMRI-PFS data for immunotherapy response assessment (N = 30).

127

128 Overview: dMRI signal models

We studied five dMRI biophysical models, accounting for restricted diffusion inside spherical cells
 and hindered diffusion in the extra-cellular space^{6,19,22}. Models can be grouped into two families
 (Fig. 2.A; see Material and Methods).

132 The first family is more general, in that it does not make any assumption on which is higher 133 between intra-/extra-cellular ADC (ADC_I and ADC_E from now on). It includes:

- 134i.Diff-in-exTD: it accounts for restricted IC diffusion within spherical cells⁶, and hindered135diffusion in the extra-cellular space, with diffusion time dependence $(TD)^{27}$ in both intra-136/extra-cellular spaces²⁸. The diffusion time quantifies the time during which water137molecules can sense cellular barriers, before the MR image is acquired.
- *Diff-in-ex*: as previous model *Diff-in-exTD*, but neglecting TD in the extra-cellular space.
 Popular techniques such as IMPULSED¹⁹ or VERDICT²⁰ are essentially implementations of this model.

141 Conversely, the second family explicitly assumes that $ADC_E > ADC_I$, similarly to related dMRI 142 techniques (e.g., Restriction Spectrum Imaging²⁹; power-law axon radius mapping⁷). It includes:

- i. *Diff-in-exTDFast*: equivalent to *Diff-in-exTD*, ensuring that $ADC_E > ADC_I$.
- 144 ii. *Diff-in-exFast*: equivalent to *Diff-in-ex*, ensuring that $ADC_E > ADC_I$.

iii. *Diff-in*: a model where it is hypothesised that due to fast, extra-cellular diffusion, the extracellular signal is negligible, and the measured signal is dominated by intra-cellular water.

146 147

145

148 **Overview: dMRI metrics**

All models enable the estimation of *volume-weighted mean cell size* (vCS_{MRI} , expressed in µm) and *intra-cellular signal fraction* (F_{MRI} , dimensionless), which can be combined into an apparent *cell density per unit volume* ($CD_{MRI} = F_{MRI}/vCS_{MRI}^3$, expressed in cell mm⁻³)²⁰. For reference, we benchmarked these metrics against routine ADC (in µm² ms⁻¹) and apparent diffusion excess kurtosis *K* (dimensionless) from diffusion kurtosis imaging (DKI)³⁰, popular dMRI indices sensitive to cancer cellularity, easy to compute from short acquisitions^{20,31}.

155

We processed HE-stained histological data with automatic cell detection³² to derive histological counterparts of vCS_{MRI} and F_{MRI} at known radiographic location. The histological metrics were: histological volume-weighted mean cell size (vCS_{histo} , in µm), intra-cellular area fraction (F_{histo} , dimensionless), and cell density per unit area (CD_{histo} , in cell mm⁻²). We compared vCS_{histo} and F_{histo} to vCS_{MRI} and F_{MRI} (Fig. 2B).

161

A one-pool model of intra-cellular diffusion provides the most histologically meaningful metrics

Fig. 3A summarises the different dMRI models, while Fig. 3B reports values of the MRI-Histology *Total Correlation Score* (TCS) for all models. TCS measures the overall correlation between histological and radiological readouts of cell size and intra-cellular fraction, and is obtained by summing Pearson's correlation coefficients between vCS_{MRI} and vCS_{histo} , and between F_{MRI} and F_{histo} (see Materials and Methods). Higher TCS point towards stronger histological-radiological correlation. Negative correlations reduce TCS, so they are penalised.

170

The bar plot in Fig. 3B highlights that dMRI models where $ADC_E > ADC_I$, shown in violet shades, provide consistently higher TCS values than models that do not make such an assumption (orange shades). We observe the highest TCS for model *Diff-in*. Note that Fig. 3 refers to TCS values obtained by fitting dMRI models only to high b-value images, as this provided the highest TCS figures. Fig. S2 reports TCS for model fitting performed to the whole set of diffusion images. In this case, TCS is lower, but again, models where $ADC_E > ADC_I$ provide the highest TCS. In Fig. S2, *Diff-in-exFast* provides the highest TCS, although this is lower than *Diff-in* TCS in Fig. 3.

178

Fig. S3 reports rankings according to additional criteria, namely: the *Histology Fidelity Criterion* (HFC), measuring the sum of absolute errors in *F* and *vCS* estimation via dMRI, and the *Bayesian*

Information Criterion (BIC)³³. BIC is commonly used in dMRI model development^{34,35}; it 181 quantifies the overall model fitting quality (penalizing model complexity), but without accounting 182 for histological information. Lower HFC and lower BIC imply better model performance. Fig. S3 183 reports the number of times, in percentage terms, that a model provides the lowest HFC and BIC 184 across our N = 25 MRI-histology cases. Results essentially confirm rankings seen on TCS: models 185 hypothesising $ADC_E > ADC_I$ are selected more frequently than models that do not do, according 186 to HFC. The model *Diff-in* is the most selected model according to both BIC and HFC (fig. S3.B; 187 fitting to high b-value images). Fig. S4 splits HFC and BIC rankings depending on the MRI 188 scanner. In all cases, models with $ADC_E > ADC_I$ (Diff-in, Diff-in-exFast, Diff-in-exFastTD) are 189 selected more frequently than models Diff-in-ex and Diff-in-ex-TD. When fitting is performed only 190 on high b-value images, *Diff-in* is the most selected model according to both BIC and HFC. 191

192

193 Computer simulations confirm model selection from MRI measurements

We performed Monte Carlo computer simulations to corroborate the model selection performed 194 on ex vivo and in vivo dMRI data. The simulations consisted in generating synthetic dMRI signals 195 according to the three dMRI protocols used in this study. We synthesised signals for a substrate 196 made of packed spherical cells (Fig. S5), a common body dMRI tissue model^{6,19,22,23}, and then 197 198 performed model selection on the synthetic signals (see Materials and Methods). Supplementary Tables S1, S2, and S3 report TCS, HFC and BIC rankings from simulated signals. Results confirm 199 that model *Diff-in* enables the best estimation of cell size and intra-cellular fraction in the vast 200 majorities of cases, thus confirming ex vivo and in vivo MRI results. 201

202

Our proposed approach: a one-compartment model of intra-cellular diffusion, fitted to high b-values

- In view of all rankings reported above, our recommended modelling approach is the *fitting a onecompartment model of restricted, intra-cellular diffusion within spherical cells to high b-values images* (\geq 1800 s/mm² *ex vivo*, \geq 900 s/mm² *in vivo*) – referred to as model *Diff-in*.
- 208

209 Cell size and density estimates from the proposed dMRI model correlate with histology

We now report on the Pearson's correlation coefficient *r* between histology, *Diff-in* and DKI metrics. We consider correlations to be weak, moderate, and strong when |r| < 0.4, $|r| \ge 0.4$ but |r| < 0.6, and $|r| \ge 0.6$.

213

Table 1 shows that the correlation between *Diff-in* F_{MRI} (intra-cellular fraction), vCS_{MRI} (cell size index) and CD_{MRI} (cell density) with their counterparts F_{histo} , vCS_{histo} and CD_{histo} are respectively weak (r = 0.19 between F_{MRI} and F_{histo}), moderate (r = 0.44 between vCS_{MRI} and

217 vCS_{histo}) and strong (r = 0.70 between CD_{MRI} and CD_{histo}). The weak correlation between F_{MRI} 218 and F_{histo} can be explained, at least in part, with the fact that F_{MRI} is a signal fraction, rather than 219 an actual volume/area fraction (unlike F_{histo}), i.e., it is influenced by T2/T1 differences between 220 intra-cellular and residual extra-cellular signals³⁶. Moreover, F_{MRI} estimation can be biased by 221 unaccounted exchange between intra-/extra-cellular water^{21,37}, which is not accounted for in our 222 signal models. Conversely, the much higher correlations between vCS_{MRI} and vCS_{histo} and 223 between CD_{MRI} and CD_{histo} , point towards the biological specificity of vCS_{MRI} and CD_{MRI} .

224

Table 1 also reports correlation coefficients for dMRI ADC and kurtosis *K*. Both ADC and *K* exhibit significant, moderate correlations with histological properties, i.e., negative/positive correlation of ADC/*K* with cell density CD_{histo} (r = -0.47 and 0.43 respectively) – a result entirely consistent with previous studies^{38,39}. Significant correlations are also seen with F_{histo} (r = 0.40, p= 0.048 between *K* and F_{histo}). These findings are in line with known literature: ADC and *K* are sensitive to the underlying tissue microstructure, but they are also unspecific, being surrogate metrics that conflate different histopathological characteristics into a single number.

232

Fig. S6 and Fig. S7 show Pearson's correlation coefficients for all possible pairs of metrics, in the 233 form of correlation matrices. Correlations among dMRI metrics are seen, as a strong negative 234 correlation between CD_{MRI} and νCS_{MRI} (r = -0.84 for model *Diff-in-exFast* fitted at high b-value). 235 This finding, which indicates that tighter cell packings per unit volume are achieved with smaller 236 cells, appears biophysically plausible, being mirrored by histological CD_{histo} and vCS_{histo} (r = -237 0.88 between CD_{histo} and νCS_{histo}). Other weak-to-moderate correlations are seen, e.g.: between 238 K and vCS_{MRI} (r = -0.47) and K and CD_{MRI} (r = 0.38), which agree with the correlations observed 239 between K and histological vCS_{histo} (r = -0.31) and CD_{histo} (r = 0.43). In general, metrics from 240 dMRI models where $ADC_E > ADC_I$ show stronger correlations with their histological counterparts 241 242 than models Diff-in-exTD and Diff-in-ex. We observe the strongest dMRI-histology correlations 243 for model *Diff-in* fitted to high b-value images.

244

245 Metrics from the proposed dMRI model reveal intra-/inter-tumour characteristics

Fig. 4 shows maps from the proposed dMRI model *Diff-in* alongside histological metrics in 3 246 mouse livers, representative of the 3 phenotypes seen in our mouse data (Control, for normal liver 247 structures; *Patinf1*, for small cell infiltration; *Patnec*, for necrosis). Visually, we observe excellent 248 co-localisation between MRI slices and histology sections. The histological details reveal higher 249 cellularity in sample *Patinfl* compared to *Control*, due to packing of small cells in between larger 250 hepatocytes, or an alternation of areas with lower/ higher cell density in sample Patnec. These 251 qualitative trends are confirmed in the histological maps F_{histo} , vCS_{histo} , CD_{histo} , with values in 252 253 physiologically plausible ranges, as for example intra-cellular fractions around 0.75 and cell sizes

of the order of 20 μ m^{40,41}. Maps F_{MRI} , vCS_{MRI} and CD_{MRI} replicate the contrasts seeing in their 254 histological counterparts F_{histo}, vCS_{histo} and CD_{histo}. Fig. S8 shows standard dMRI metrics, 255 namely ADC and kurtosis excess K, in the same mouse livers. Visual trends highlight that the 256 higher cell density of sample Pat_{infl} translated to remarkably reduced ADC and increased K 257 compared to the Control. Lastly, Fig. S9 shows F_{MRI} , vCS_{MRI} and CD_{MRI} maps from another model 258 (Diff-in-exFast). Fig. S10 instead shows maps of the other metrics provided by models Diff-in-259 exFast and Diff-in (intrinsic cytosol diffusivity $D_{0,I}$ and asymptotic ADC_E , $D_{E,\infty}$). The figures 260 highlight that overall, spatial trends seen in maps from the selected model *Diff-in* agree with those 261 seen in Diff-in-exFast, but metrics from the latter appear noisier. Metrics $D_{0,I}$ and $D_{E,\infty}$ show 262 limited between-sample contrast, and are difficult to validate histologically. 263

264

270

Table S4 reports qualitative per-sample mean and standard deviation of all MRI and histology metrics in mice. F_{MRI} slightly underestimates F_{histo} , while vCS_{MRI} slightly overestimates vCS_{histo} . We speculate that the discrepancies may be due, at least in part, to unaccounted factors such as variability in intrinsic cell shape/cytosol diffusivity⁴² or water exchange²¹, and by the difficulty of relating accurately 2D histology to 3D MRI⁴³.

Fig. 5 shows F_{MRI} , vCS_{MRI} and CD_{MRI} maps in patients, alongside biopsies. Histopathological 271 assessment highlights the variety of characteristics that can coexist within advanced solid tumours, 272 e.g.: areas of fibrosis; localised areas of tightly packed cancer cells, sourrounded by stromal fibres; 273 necrosis. dMRI F_{MRI} , vCS_{MRI} , CD_{MRI} show contrasts that are plausible with such histopathological 274 features. For example, in a breast cancer liver metastasis in Fig. 5, we observe a core of low intra-275 cellular fraction F_{MRI} and low cell density CD_{MRI} , compatible with necrosis. In a HCC case instead, 276 we see areas of high F_{MRI} and high CD_{MRI} , sourrounded by lower F_{MRI} and lower CD_{MRI} , 277 potentially indicating the alternation of high cell densities with fibrotic tissue. Fig. S11 shows 278 routine dMRI ADC and K in the same tumours. Spatial trends are also compatible with the 279 histology, e.g., high ADC and low K are seen in the necrotic core of the breast cancer tumour. 280 Supplementary Fig. S12 shows F_{MRI} , vCS_{MRI} and CD_{MRI} from model Diff-in-exFast. Image 281 contrasts match visually those seen in the same metrics from model Diff-in (the proposed 282 approach), giving confidence of the overall robustness of the biophysical modelling framework. 283 Nevertheless, maps appear noisier. Fig. S13 shows intra-cellular cytosol diffusivity $D_{0,I}$ 284 asymptotic ADC_E $(D_{E,\infty})$ in the same tumours. Their speckled appearance suggests that these 285 metrics are difficult to measure accurately in vivo^{19,44}. 286

287

Metrics from the proposed dMRI model stratify the risk of cancer progression in immunotherapy

Finally, we demonstrate the potential utility of the proposed liver dMRI model in an 290 exemplificatory response assessment task. Fig. 6 reports on the PFS stratification based on Diff-in 291 metrics. Panels on the left report results from Kaplan-Meier analyses, log-rank tests and Cox 292 regressions performed after binarising dMRI metrics (higher/lower than the median of the cohort). 293 294 Panels on the right report results from Cox regressions assessing the continuous dependence of 295 PFS on Diff-in metrics. We detect a statistically significant dependence of the risk of progression on baseline vCS_{MRI} (log-rank test: p = 0.047, Fig. 6C) and CD_{MRI} (log-rank test: p = 0.035, Fig. 296 6E). These differences correspond to statistically significant Hazard Ratios (HRs) from Cox 297 regression (HR = 0.47, p = 0.050 for binarised vCS_{MRI} ; HR = 2.36, p = 0.043 for binarised CD_{MRI}). 298 The risk of progression is about twice as high in patients whose baseline cell size vCS_{MRI} is smaller 299 than the median vCS_{MRI} , or whose cell density CD_{MRI} is higher than the median CD_{MRI} . 300 Importantly, we obtained similar results when νCS_{MRI} and CD_{MRI} were not binarised, but rather 301 used as continuous predictors in Cox regressions (right panels in Fig. 6). In this latter case, the HR 302 was statistically significant for vCS_{MRI} (HR = 0.65, p = 0.034, Fig. 6D), and it approached 303 statistical significance for CD_{MRI} (HR = 1.40, p = 0.055, Fig. 6F). These association are not 304 confounded by age, sex or baseline tumour volume (Supplementary Table S5; HR = 0.59, p = 0.02305 for vCS_{MRI} ; HR = 1.65, p = 0.01 for CD_{MRI}). 306

307

Fig. 7 and supplementary Fig. S14, Fig. S15 and Fig. S16 report on response assessment based on on all other dMRI metrics (routine *ADC* and *K* in Fig. 7; cytosol diffusivity $D_{0,I}$ for model *Diff-in* in Fig. S14; vascular fraction f_V in Fig. S15; all metrics from model *Diff-in-exFast* in Fig. S16). While the estimated HRs for metrics vCS_{MRI} , F_{MRI} and CD_{MRI} from dMRI model *Diff-in-exFast* are in the same direction as those from model *Diff-in*, their association with the probability of progression is weaker (HR = 1.53, p = 0.05 for CD_{MRI} ; Table S5). We do not detect any association between baseline *ADC* and *K* and the probability of progression (Fig. 7 and Table S5).

315

316 **Discussion**

The latest liver dMRI models aim to disentangle intra-cellular and extra-cellular water 317 contributions to the total signal^{6,19,22,23}. This powerful approach enables the estimation of 318 innovative tissue property maps, but its clinical deployment is hampered by the high number of 319 unknown tissue parameters to estimate, which requires impractically long dMRI 320 acquisitions^{19,45,46}. With this challenge in mind, this paper delivers a practical implementation of a 321 two-compartment dMRI signal model, tailored for liver imaging, and truly feasible in the clinic. 322 Through histology-informed model selection, we design a compact dMRI framework consisting 323 of fitting a one-pool model of restricted intra-cellular diffusion to highly DW images. The 324 framework provides cell size and density estimates that correlate with histology, and which enable 325 the stratification of the risk of cancer progression under immunotherapy. 326

327

To find the optimal dMRI signal implementation, we analysed co-localised dMRI and histology 328 data (N = 25) from fixed mouse livers and from cancer patients. We compared 5 signal models, 329 each fitted according to two distinct strategies, and ranked them for their ability to estimate intra-330 cellular fraction and cell size, as seen on histology. Rankings unequivocally suggest the highest 331 332 radiological-histological agreement is obtained by fitting a single-compartment model of restricted diffusion within spherical cells - a model here referred to as Diff-in -, to images acquired with b-333 values higher than approximately 900 s/mm² in vivo and 1800 s/mm² ex vivo. Interestingly, our 334 central result, confirmed by Monte Carlo computer simulations, points towards the fact that 335 simpler models of diffusion can provide the highest fidelity to the underlying histology, if deployed 336 in appropriate measurement regimes. In practice, our approach suggests that focussing on 337 measurement regimes where the signal is dominated by intra-cellular diffusion, may enable the 338 deployment of simpler models, which still suffice to capture salient microstructural features^{7,47–49}. 339 Notably, our model selection results are consistent with the fact recent estimates of the extra-340 cellular liver ADC, as high as 2.5 μ m²/ms¹⁹. Such a high ADC_E implies that the extra-cellular 341 signal would decay to roughly 5% or less of its non-DW value even for b-values of 1200 s/mm² 342 $(\exp(-b ADC_E) \approx 0.05 \text{ for } b = 1200 \text{ s/mm}^2 = 1.2 \text{ ms}^{-1} \text{ } \mu\text{m}^2 \text{ and } ADC_E = 2.5 \text{ } \mu\text{m}^2 \text{ ms}^{-1})$, justifying 343 the use of single-compartment model of intra-cellular diffusion^{7,44,50}. 344

345

Importantly, we conducted dMRI model selection using a variety of criteria, namely: TCS (overall 346 correlation between dMRI and histology), HFC (accuracy in histological property estimation via 347 dMRI), and BIC³⁵ (dMRI model quality of fit, penalising model complexity). In general, all criteria 348 point towards the same direction, with model Diff-in fitted to high b-value images being the top-349 ranking model. We would also like to emphasise that while we used 15 in vivo dMRI scans for 350 both model design and for the clinical demonstration, the same liver dMRI model implementation 351 352 (i.e., fitting model *Diff-in* on high b-value images) would have been selected had we only looked at the ex vivo mouse data or at in silico signals (Fig. S4, Tables S1 to S3). This fact gives confidence 353 on the robustness and generalisability of our model design. Another important observation is that 354 both TCS and HFC, which are histology-informed, suggest that models constraining the extra-355 cellular ADC to be higher than the intra-cellular ADC, outperform models without such a 356 constraint. Such a better performance does not stand out as clearly when looking at BIC rankings 357 instead (e.g., Fig. S3.A, Fig. S4.A, Fig. S4.B, Fig. S4.C). This minor discrepancy can be 358 understood considering that a good fitting quality may not necessary imply accurate parameter 359 estimation in presence of noise^{26,44}. It also stresses the importance of informing dMRI modelling 360 with histology, for improved biological specificity. 361

362

After selecting a practical dMRI model implementation, we investigated its utility in an exemplificatory response assessment task. Immunotherapy has shown promise in several cancers¹⁶. However, only a small fraction of patients truly benefits from this class of drugs, and their identification prior to treatment is extremely challenging¹⁷. With this in mind, we investigated

whether it is possible to stratify the probability of progression under immunotherapy given baseline 367 dMRI metrics within liver tumours (N = 30). Several, independent statistical tests consistently 368 point towards the fact that smaller baseline dMRI cell sizes and higher dMRI cell densities are 369 associated to faster cancer progression (shorter PFS). To our knowledge, this is the first time that 370 such advanced dMRI markers have been tested for patient stratification in immunotherapy in vivo. 371 The deleterious impact of higher cell density on PFS is in line with other studies focussing on 372 different treatments, where higher tumour cellularity has been associated with higher cancer 373 aggressiveness or worse prognosis. In CRC liver metastasis resection, for example, high cell 374 density in resected metastases has been associated to shorter disease-free survival⁵¹. Conversely, 375 in breast cancer, lower tumour cellularity has been associated to pathologic complete response in 376 chemo-free dual HER2 blockade treatment (for HER2-positive breast cancer)⁵², as well as longer 377 survivals in neoadjuvant chemotherapy⁵³. The significant association between PFS and dMRI cell 378 size/density reported here is promising, and motivates future studies to confirm it. 379

We benchmarked the proposed dMRI approach against well-established DKI apparent diffusion 381 and kurtosis coefficients (ADC and K)³⁰. ADC and K are easy to compute with compact dMRI 382 acquisitions, and are sensitive to cancer cellularity⁴⁶, a fact confirmed by our data. However, in 383 our cohort, neither of ADC and K showed statistically significant associations with clinical PFS. 384 This may due, at least partly, to the fact that ADC and K are semi-quantitative, protocol-dependent 385 metrics, whose value can change as function of factors as the diffusion time^{46,54}. Here, we did not 386 perform inter-scanner harmonisation deliberately, to stress the quantitative nature of our cell 387 size/density mapping approach, which inherently accounts for inter-scanner protocol differences. 388 However, it is possible that better performances for semi-quantitative ADC and K may be obtained 389 by adopting inter-scanner harmonisation⁵⁵. 390

391

380

We would like to acknowledge the following potential limitations. Firstly, our sample size (N = 25 for model development; N = 30 for the clinical demonstration) is relatively small. This paper provides a first demonstration of the potential utility of the proposed *Diff-in* approach. The demonstration is unique of its kind, since it reports heretofore undescribed dMRI-based stratification in immunotherapy. Nonetheless, while works proposing related dMRI techniques relied on similar^{23,36}, if not even smaller^{19,20}, sample sizes, we acknowledge that our exploratory findings require further confirmation in larger cohorts.

399

400 Secondly, we point out that results from any dMRI-histology comparison should always be taken 401 with care. Here we related dMRI metrics obtained *in vivo* to histological indices from biopsies. 402 While we were able to identify the tumours from which the biopsies were taken, we could not 403 identify exactly the tumour area that was biopsied. This may imply that the biopsies are not fully 404 representative of the tumour microenvironment in its entirety. Also, and most importantly,

histology has its own limitations, since it provides cell property estimates that may not be, *per se*,
fully accurate. For example, routine HE histology is an inherently 2D technique, unlike 3D MRI.
Moreover, it is affected by artifacts (e.g., due to dehydration, paraffin embedding, imperfect
staining, cutting, etc⁵⁶), and the automatic processing of large fields-of-view requires trading off
between sensitivity and specificity. We took steps to mitigate these issues, e.g., by accounting for
biases due to tissue shrinkage. Nonetheless, our histology-derived estimates of cell properties are
likely biased versions of the true figures.

412

We would also like to acknowledge that the proposed dMRI approach neglects other potentially relevant microstructural properties, such as water exchange between intra-/extra-cellular spaces^{21,37}, presence of cell size/cytosolic diffusivity distributions^{42,57}, or intra-compartmental T2 or T1³⁶. On the one hand, ignoring these properties may have biased the estimation of F_{MRI} and $vCS_{MRI}^{21,37}$. On the other hand, properties such as exchange rates, overlooked in our model, may be relevant markers of cellular stress *per se*. In future, we plan to incorporate these properties in our models, while ensuring the clinical feasibility of the dMRI protocols required to fit them.

420

To conclude, this study delivers a practical liver dMRI signal model consisting of a single-421 compartment of restricted diffusion within spherical cells, which should be fitted to b-values higher 422 than, approximately, 900 s/mm² in vivo. This model offers estimates of cell size and cell density 423 that are correlated to the underlying histology, and which may provide complementary information 424 to routine volumetric tumour burden assessment, for example by stratifying the risk of cancer 425 progression in immunotherapy. Striving to bringing precision imaging one step closer to the clinic, 426 we release our approach as an easy-to-use, open-source Python implementation, which will be 427 428 freely accessible online.

429

430 Methods

431 **dMRI models**

432 Common biophysical body dMRI signal models^{6,19,20,50,58,59} describe the signal as arising from 433 three, non-exchanging proton pools: vascular water; restricted, intra-cellular water; hindered, 434 extra-cellular, extra-vascular water. The dMRI signal for a PGSE measurement at b-value b, 435 gradient duration/separation δ/Δ , and echo time TE is

436

437

$$s = s_0 \left(f_V e^{-\frac{TE}{T_2_V}} a_V + (1 - f_V) \left(f_I e^{-\frac{TE}{T_2_I}} a_I + (1 - f_I) e^{-\frac{TE}{T_2_E}} a_E \right) \right). (1)$$

438

439 Above, s_0 is the apparent proton density, f_V is the voxel vascular signal fraction, f_I is the tissue 440 intra-cellular signal fraction, $T2_V/T2_I/T2_E$ and $a_V/a_I/a_E$ are compartment-wise T2 and diffusion-441 weighting factors.

442 a_V captures intra-voxel incoherent motion (IVIM) effects⁶⁰. In vivo, the IVIM vascular ADC 443 ranges approximately⁶¹ [15; 60] μ m² ms⁻¹. For this reason, for b > 100 s/mm², the vascular signal 444 vanishes ($a_V \approx 0$), and Eq. (1) reduces to¹⁹

445

$$s = s_0 (1 - f_V) \left(f_I e^{-\frac{TE}{T_2}} a_I + (1 - f_I) e^{-\frac{TE}{T_2}} a_E \right). (2)$$

A common model for a_I in Eq. 2 is that of restricted diffusion within spheres of diameter $L^{19,20}$:

 $a_I = e^{-b ADC_I(\delta, \Delta, D_{0,I}, L)}, \quad (3)$

447

446

448

449

450

- 451
- 452 where
- 453

454
$$ADC_{I} = \frac{2}{D_{0,I}\delta^{2}(\Delta-\delta/3)} \sum_{m=1}^{\infty} \lim_{m \to \infty} \frac{\alpha_{m}^{-4}}{\alpha_{m}^{2}R^{2}-2} \left(2\delta - \frac{1}{2}\delta\right)$$

455
$$\frac{2 + e^{-\alpha_m^2 D_{0,I}(\Delta - \delta)} - 2e^{-\alpha_m^2 D_{0,I} \delta} - 2e^{-\alpha_m^2 D_{0,I} \Delta} + e^{-\alpha_m^2 D_{0,I}(\Delta + \delta)}}{\alpha_m^2 D_{0,I}} \right)$$
(4)

456

457 is the Gaussian phase distribution approximation of the intra-cellular ADC⁶². Above, α_m is the *m*-458 th root of $\alpha_m R J'_{3/2}(\alpha_m R) - 0.5 J_{3/2}(\alpha_m R) = 0$, $J_{3/2}(x)$ is the Bessel function of the first kind and order 459 3/2, and $J'_{3/2}(x)$ its first-order derivative. ADC_I depends on the intrinsic cytosol diffusivity $D_{0,I}$ and 460 on the cell size L = 2R (*R*: radius; *L*: diameter). Noting that dMRI-derived *L* represents a volume-461 weighted mean cell size statistics^{7,42}, we will refer to it as *volume-weighted cell size* (*vCS*).

462

463 Conversely, the extra-cellular, extra-vascular signal may be described in terms of hindered 464 diffusion in a tortuous space^{19,27,59}:

 $a_{E}(b,\Delta) = e^{-b ADC_{E}(\Delta,D_{E,\infty},\beta)},$ (5)

465

466

467

468

with

469 $ADC_E(\Delta, D_{E,\infty}, \beta) = D_{E,\infty} + \frac{\beta}{\Lambda}.$ (6) 470 471 In Eq. 6, $D_{E,\infty}$ is the asymptotic⁵⁹ ADC_E for $\Delta \to \infty$. 472 473 The 5 implementations of the two-compartment model 474 We investigated 5 implementations of Eq. 2, divided into two families. The first family includes 475 models that do not make assumptions on which of ADC_I/ADC_E is higher: 476 *Diff-in-exTD*: the most general model, relying on the full expression of ADC_E in Eq. 6; i. 477 ii. *Diff-in-ex*: a simpler implementation of *Diff-in-exTD* that neglects extra-cellular TD ($\beta = 0$ 478 in Eq. 6). 479 In the second family of models, we constrain $ADC_E > ADC_I$. It includes 480 Diff-in-exTDFast: equivalent to Diff-in-exTD, with the lower bound for $D_{E,\infty}$ ensuring i. 481 $ADC_E > ADC_I$ for any *L*. 482 *Diff-in-exFast*: equivalent to *Diff-in-ex*, but again ensuring that $ADC_E > ADC_I$ for any L. ii. 483 iii. Diff-in: a model where the extra-cellular signal is negligible compared to the intra-cellular 484 one, due to ADC_E being much larger than ADC_I , so that Eq. 2 simplifies to 485 486 $s = s_0 (1 - f_V) f_I e^{-\frac{TE}{T_2}} a_I (b, \delta, \Delta, D_{0,I}, L). (7)$ 487 488 In all models we used $T2_I \approx T2_E \doteq T2_T$, given the challenge of resolving accurately multiple T2 489 constants^{20,36}. 490 491 492 Fitting We fitted the 5 models using custom-written Python routines, based on objective function 493 minimisation initialised by a grid search. The objective function was $f_{obj} = -ln(\lambda)$, where λ is 494 the offset-Gaussian likelihood³⁴. Fitting provides estimates of vCS and voxel intra-cellular signal 495 fraction 496 497 $F = (1 - f_v) f_i$. (8) 498 499

We also combined *vCS* and *F* into a cell density per unit volume²⁰

500 501

 $CD = \frac{F}{\nu CS^3}.$ (9)

503

502

504 **Preclinical data**

505 <u>Animals</u>

We obtained data from 7 fixed livers of NOD.Cg-Prkdc^{scid} IL2rg^{tm1WjI}/SzJ mice. All experimental 506 protocols were approved and monitored by the Vall d'Hebron Institute of Research Animal 507 Experimentation Ethics Committee (CEEA; registration number 68/20) in accordance with 508 relevant local and EU regulations. We studied six livers from mice implanted with cells derived 509 from biopsies of prostate cancer patients, as part of an ongoing study, plus an additional liver from 510 a mouse without any implantation. We implanted one tumor biopsy core with growth factor-511 enriched Matrigel (Corning) subcutaneously in the flank of each mice. We derived tissue from the 512 following biopsies: iliac bone metastasis biopsy (metastatic castration-resistant prostate cancer, 513 presenting with bone metastasis and Gleason score 3+4 adenocarcinoma); prostate biopsy (patient 514 with metastatic hormone-sensitive prostate cancer, presenting with bone metastasis and Gleason 515 score 5+4 adenocarcinoma); two liver biopsies (patient with metastatic castration-resistant prostate 516 cancer, presenting with bone and visceral metastasis and Gleason score 4+4 acinar 517 adenocarcinoma; patient with metastatic hormone-sensitive prostate cancer, presenting with bone 518 and liver metastasis and Gleason score 4+4 adenocarcinoma). After implantation, we measured 519 tumour size using calipers and monitored mouse weight weekly, sacrificing animals by cervical 520 dislocation under general anesthesia when tumour volume exceeded 2000 mm³. We collected the 521 livers, fixed them overnight in formalin, and transferred them to phosphate-buffered saline (PBS) 522 solution. 523

524

525 <u>MRI</u>

We scanned livers on a 9.4T Bruker Avance system at room temperature. Livers were tightened 526 with sewing thread to a histology cassette and placed into a Falcon[®] tube, filled with PBS solution. 527 A 1-channel birdcage coil was used (excitation/reception). The protocol included a T2-weighted 528 fast spin echo sequence (resolution: 144 μ m × 144 μ m × 2.216 mm) and PGSE dMRI (Fig. S17A; 529 TR = 2700 ms; resolution: $386 \mu m \times 386 \mu m$; matrix size: 86×86 ; 4 slices, 2.216 mm-thick, NEX 530 = 1). The protocol featured: $\delta = 10 \text{ ms}, \Delta = \{15, 30\} \text{ ms}, 10 \text{ linearly spaced b-values for each } \Delta$ 531 (minimum/maximum nominal b: 0/2800 s/mm²). DW images corresponding to $\Delta = 15$ ms were 532 acquired at each of TE = $\{31, 45, 65\}$ ms, and to $\Delta = 30$ ms at each of TE = $\{45, 65\}$ ms. We i) 533 denoised dMRI scans with Marchenko-Pastur Principal Component Analysis (MP-PCA) Python 534 denoising⁶³ (kernel: 7×7×3), ii) mitigated Gibbs ringing (MrTrix3 local sub-voxel shift method⁶⁴), 535

and iii) corrected temporal signal drifts by assessing signal changes in a PBS solution region,
 accounting for TE (PBS T2: 500 ms).

Finally, we fitted the Diff-in-exTD, Diff-in-exTDFast, Diff-in-ex, Diff-in-exFast and Diff-in models 538 voxel-by voxel (tissue parameter bounds: [0; 1] for f_I ; [0.8; 2.6] $\mu m^2 ms^{-1}$ for $D_{0,I}$; [8; 40] μm for 539 vCS; [0.8; 2.6] μ m² ms⁻¹ for $D_{E,\infty}$ in models *Diff-in-ex* and *Diff-in-exTD* and [1.75; 2.6] μ m² ms⁻¹ 540 in models *Diff-in-exFast* and *Diff-in-exTDFast*; [0; 10] μm^2 for β in models *Diff-in-ex-TD* and 541 Diff-in-exTDFast). For fitting, we fixed f_V and $T2_T$ to values obtained through a a two-pool 542 vascular-tissue model⁶⁵ (fitting bounds: [0; 1] for f_V ; [5; 80] ms for $T2_T$). Fitting was performed 543 i) on all images with b > 1000 s/mm² (suppressing vascular signals, referred to as *fitting on whole* 544 *image set*); ii) on b > 1000 s/mm² images (*high b-value fitting*). In our *ex vivo* data, the vascular 545 signal captures PBS solution contamination (PBS ADC: roughly 2.4 µm² ms⁻¹). For this reason, 546 we adopted a b-value threshold of 1000 s/mm² to achieve acceptable PBS signal suppression. We 547 used instead a minimum b-value of 1800 s/mm² for high b-value fitting (minimising extra-cellular 548 contributions), given the reduction in intrinsic tissue diffusivity expected ex vivo. 549

550

551

For comparison, we computed ADC and apparent diffusion excess kurtosis K by fitting

552

553

 $s = s_0 e^{-b ADC + \frac{1}{6}K(b ADC)^2}$ (10)

554

555

556

to DW images acquired at TE = 45 ms, $\Delta = 30$ ms, with in-house Python code.

557 <u>Histology</u>

After MRI, samples underwent histology. We cut two 4 µm-thick histological sections at known position, stained them with HE, and digitised them (Hamamatsu C9600-12 slide scanner; 0.227 µm resolution). An experienced pathologist (S.S.) inspected images qualitatively. We then processed them with the automatic cell detection tool of QuPath³², obtaining per-cell area *A* and diameter $l = \sqrt{\frac{4}{\pi}A}$. Afterwards, we split images into 386 µm × 386 µm patches (matching the MRI resolution), computing patch-wise histological volume-weighted cell size vCS_{histo} , intra-cellular area fraction F_{histo} and cell density per unit area CD_{histo} ⁴². vCS_{histo} , defined as

565

566
$$\nu CS_{histo} = \left(\frac{\langle l^7 \rangle}{\langle l^3 \rangle}\right)^{\frac{1}{4}}, (11)$$

567

is a more accurate counterpart of dMRI cell size than the arithmetic mean^{7,42} $aCS_{histo} = \langle l \rangle$. 568 We accounted for biases coming from: i) estimating the size of 3D objects from 2D views (bias 569 1), ii) tissue shrinkage (bias 2), by rescaling vCS_{histo} and CD_{histo} . The final vCS_{histo} estimate was 570 1.4616 times larger than the value obtained from direct image processing $(1.4616 = 1.2732 \times 1.148;$ 571 1.2732, derived from the theory of spherical caps, accounts for bias 1; 1.148 accounts for bias 2, 572 and corresponds to a plausible shrinkage of 12.9% following dehydration, clearing and paraffin 573 embedding⁵⁶). The final CD_{histo} estimate was 1.318 times smaller than the value derived from 574 direct image processing, since 1 mm² of shrunk tissue corresponds to 1.148×1.148 mm² = 1.318575 mm² of unprocessed tissue (plausible shrinkage 12.9%⁵⁶). Lastly, we co-registered histological 576 maps to MRI⁴² using DiPv⁶⁶. 577

578

579 Clinical data

580 <u>Cohort</u>

We obtained data from patients suffering from advanced solid tumours, recruited for an ongoing 581 imaging study approved by the Vall d'Hebron University Hospital Ethics committee 582 (PR(AG)29/2020). Patients, eligible for a phase I immunotherapy trial at VHIO (Barcelona, 583 Spain), provided informed written consent to participate in the imaging study. We included 33 584 patients with liver malignancies (mean/std of age: 62.91/12.34 year; 16 male, 17 female), of which 585 3 suffered from primary HCC, while 30 had liver metastases from different primary cancers (10 586 colon, 8 melanoma, 3 rectal, 2 ovarian, 2 gastric, 2 breast, 1 renal, 1 endometrial, 1 ureteral). We 587 obtained baseline dMRI scans (i.e., acquired immediately before starting immunotherapy), and 588 digitised HE-stained biopsies from one of the imaged liver tumours. We obtained biopsies from 589 18 patients (6 scanned at 1.5T, 12 at 3T), collected after baseline dMRI. 30 out of 33 patients 590 finally entered the immunotherapy trial after screening; for them, a clinical outcome in the form 591 of PFS was available. PFS represents the lag between therapy starting date and progression or 592 death (whichever occurs first), with progression determined via RECIST¹³, or in case of 593 established clinical worsening. 594

- 595
- 596

MRI

We imaged patients at the level of the abdomen. We scanned 11 patients on a 1.5T Siemens Avanto 597 scanner using the vendor 18-channel body coil for detection. The protocol included a T2-weighted 598 fast spin echo scan (resolution: $1.4 \times 1.4 \times 5 \text{ mm}^3$; 32 slices; TR = 4500 ms; TE = 82 ms; echo 599 train length: 29; NEX = 8; GRAPPA = 2) and fat-suppressed DW TRSE (Fig. S17B) EPI (dMRI 600 scan time: 16 minutes). It featured: resolution: $1.9 \times 1.9 \times 6 \text{ mm}^3$; 32 slices; TR = 7900 ms; 601 bandwidth 1430 Hz/pixel; averaging of 3 orthogonal diffusion directions \times 2 signal averages 602 (effective NEX = 6); GRAPPA factor of 2; 6/8 partial Fourier imaging. The dMRI protocol 603 consisted of $b = \{0, 50, 100, 400, 900, 1200, 1600\}$ s/mm², each for TE = $\{93, 105, 120\}$ ms. One 604 additional image (b = 0 s/mm²; TE = 93 ms) was acquired with reversed phase encoding polarity. 605

606The gradient timings (Fig. S17B) were: $\delta_1 = 8.9 \text{ ms}$, $\delta_2 = 17.6 \text{ ms}$, $\delta_3 = 20.4 \text{ ms}$, $\delta_4 = 6.0 \text{ ms}$, $\Delta_{1,2}$ 607= 17.4 ms and $\Delta_{1,4} = 63.9 \text{ ms}$ when TE = 93 ms; $\delta_1 = 13.2 \text{ ms}$, $\delta_2 = 19.3 \text{ ms}$, $\delta_3 = 24.8 \text{ ms}$, $\delta_4 = 7.7$ 608ms, $\Delta_{1,2} = 21.7 \text{ ms}$ and $\Delta_{1,4} = 74.2 \text{ ms}$ when TE = 105 ms; $\delta_1 = 18.9 \text{ ms}$, $\delta_2 = 21.0 \text{ ms}$, $\delta_3 = 30.5$ 609ms, $\delta_4 = 9.5 \text{ ms}$, $\Delta_{1,2} = 27.5 \text{ ms}$ and $\Delta_{1,4} = 87.5 \text{ ms}$ when TE = 120 ms. The b-value is

610

611
$$b = \gamma^2 G^2 \left(\delta_1^2 (\Delta_{1,2} - \delta_1) + \frac{2}{3} (\delta_1 + \delta_2)^3 + (\delta_1 + \delta_2 - \delta_3)^2 (\Delta_{1,4} - \Delta_{1,2} - \delta_2 - \delta_3) \right). (12)$$

612

We scanned 22 more patients on a 3T GE SIGNA Pioneer scanner, using the vendor 48-channel 613 torso coil for signal reception, with 32 channels enabled for detection. The protocol included a 614 respiratory-gated T2-weighted fast spin echo scan (resolution: $1.4 \times 1.4 \times 6 \text{ mm}^3$; 32 slices; TR = 615 616 4615 ms; TE = 52.86 ms; echo train length: 16) and respiratory-gated, fat-suppressed PGSE (Fig. S10A) EPI (dMRI scan time: 16 minutes). It featured: resolution: $2.4 \times 2.4 \times 6 \text{ mm}^3$; 32 slices; TR 617 = 6000 ms; bandwidth 1953 Hz/pixel; averaging of 3 orthogonal diffusion directions \times 2 signal 618 619 400, 900, 1200, 1500} s/mm², each for TE = $\{75, 90, 105\}$ ms. The gradient timings (Fig. S17A) 620 were: gradient duration $\delta = \{0.0, 3.9, 5.2, 9.2, 15.0, 18.2, 21.0\}$ ms for TE = 75 ms, $\delta = \{0.0, 3.9, 5.2, 9.2, 15.0, 18.2, 21.0\}$ 621 622 33.0, 28.7, 31.8, 34.7} ms for TE = 75 ms and $\Delta = \{0.0, 27.8, 29.0, 33.0, 37.0, 39.6, 42.3\}$ ms for 623 TE = 90 ms and TE = 105 ms. 624

625

dMRI post-processing consisted of slice-wise Python MP-PCA denoising (kernel: 5×5)⁶³; 626 MRTrix3 Gibbs unringing⁶⁴; motion correction via affine co-registration⁶⁷; FSL distortion 627 correction⁶⁸ (1.5T data only). An experienced radiologists (R.P.L.) segmented tumours on the T2-628 w scan, enabling per-patient tumour volume computation. Afterwards, we warped the tumour mask 629 to dMRI using ANTs⁶⁹ non-linear co-registration, and fitted the 5 dMRI models, fixing again f_V 630 and $T2_T$ to previously computed values⁶⁵ (fitting bounds: [0; 1] for f_V ; [20; 140] ms for $T2_T$; [0; 631 1] for f_I ; [0.8; 3.0] μ m² ms⁻¹ for $D_{0,I}$; [8; 40] μ m for vCS; [0.8; 3.0] μ m² ms⁻¹ for $D_{E,\infty}$ in models 632 Diff-in-ex and Diff-in-exTD, and [1.75; 3.0] um² ms⁻¹ in models Diff-in-exFast and Diff-in-633 exTDFast; [0; 10] μm^2 for β in models *Diff-in-ex-TD* and *Diff-in-exTDFast*). 634

635

636 We fitted the 5 dMRI models i) on images acquired at a b-value $b > 100 \text{ s/mm}^2$, to suppress 637 vascular signals (*fitting to the whole image set*); ii) to $b > 900 \text{ s/mm}^2$ images, to also minimize 638 extra-cellular contributions (*high b-value fitting*). For scans performed on the 1.5T Siemens 639 system: i) we used $\Delta_{1,2} + \delta_2$ in place of Δ in Eq. 6 (Fig. S10B), ii) we replaced Eq. 4 with a 640 numerical implementation of restricted diffusion within spheres, based on Radial Basis Function 641 interpolation of synthetic signals generated for DW-TRSE with Monte Carlo simulations⁷⁰.

For both scanners, we also computed ADC and excess kurtosis *K* by fitting Eq. 10 on b > 100s/mm² images (shortest TE), with in-house Python code.

645

642

646 <u>Histology</u>

We performed ultrasound-guided biopsies of one liver tumour at the Barcelona Vall d'Hebron 647 University Hospital (Spain). The biological material underwent standard processing, HE staining 648 and digitalisation (Hamamatsu C9600-12 slide scanner; resolution: 0.454 µm). An experienced 649 pathologist (S.S.) assessed the images and drew a region-of-interest (ROI) outlining the tumours. 650 In parallel, an experienced radiologist (R.P.L.) inspected ultrasound and MR images, outlining the 651 652 biopsied tumour on the latter. We processed HE data with QuPath and computed per-biopsy vCS_{histo} , F_{histo} and CD_{histo} , as previously described. Finally, we rescaled vCS_{histo} and CD_{histo} , 653 by multiplying vCS_{histo} from image processing by 1.503 (1.503 = 1.1806×1.2732, where 1.2732 654 accounts for biases from 2D sectioning, and 1.1806 accounts for a plausible tissue shrinkage of 655 15.3% following fixation, dehydration, clearing and paraffin embedding⁵⁶). The final CD_{histo} 656 estimate was instead 1.3938 times smaller than the value derived from direct image processing, 657 since 1 mm² of shrunk tissue corresponds to 1.1806×1.1806 mm² = 1.3938 mm² of unprocessed 658 tissue for a shrinkage factor of 15.3%⁵⁶. 659

660

661 Statistical analyses

662 <u>dMRI model selection</u>

663 We carried out model selection independently for each of the two fitting strategies. The MRI-664 histology *Total Correlation Score* (TCS) selects the model providing the highest Pearson's 665 correlation between vCS_{MRI} and vCS_{histo} , and between F_{MRI} and F_{histo} . It is defined as

666

667

 $TCS = r(vCS_{MRI}, vCS_{histo}) + r(F_{MRI}, F_{histo}), (13)$

668

669 where $r(vCS_{MRI}, vCS_{histo})$ and $r(F_{MRI}, F_{histo})$ are the correlation coefficients of vCS_{MRI} and 670 F_{MRI} with histological vCS_{histo} and F_{histo} . The correlation between CD_{MRI} and CD_{histo} was not 671 included in Eq. 13 since CD_{MRI} is determined analytically from vCS_{MRI} and F_{MRI} . For TCS 672 computation, we pooled together mouse and human data (N = 25).

673

674 We also performed model selection using a *Histology Fidelity Criterion* (HFC), and popular 675 *Bayesian Information Criterion* (BIC)^{33,34}. HFC rewards the models providing the best accuracy

in the numerical estimation of histological cell size and intra-cellular fraction estimation, i.e.,
 minimising

678

679

680

681

682

683

684

685

686

687

688

689

$$HFC = \frac{|vCS_{MRI} - vCS_{histo}|}{vCS_{histo}} + \frac{|F_{MRI} - F_{histo}|}{F_{histo}}.$$
 (14)

Information on CD_{MRI} and CD_{histo} was not included in Eq. 14 since CD_{MRI} is not a degree of freedom of the dMRI models (it is determined analytically from vCS_{MRI} and F_{MRI}). BIC selects the model providing the best goodness of fit, penalising complexity, by minimising

$$BIC = Pln(N) - ln(\lambda). (15)$$

 λ is the maximised likelihood, and *P*/*N* are the number of model parameters/signal measurements. We performed BIC selection voxel-wise, followed by majority voting across voxels.

690 <u>Simulated dMRI model selection</u>

We synthesised signals via Monte Carlo diffusion random walks for each of the three dMRI 691 protocols of this study, using the MCDC simulator⁷⁰. We seeded walkers in a substrate made of 692 spherical cells of identical diameter^{6,19,22,23} (Fig. S5), controlling the intra-sphere fraction F by 693 adding gaps of increasing size in-between abutting spheres, packed in an ideal cubic lattice. We 694 probed four F values (0.197, 0.323, 0.406, 0.523) and four sphere diameters for each F (8, 16, 22) 695 and 30 μ m). We varied intra-/extra-sphere diffusivities (10×10 values; [0.8; 2.6] μ m² ms⁻¹ for the 696 ex vivo protocol and $[0.8; 3.0] \,\mu\text{m}^2 \text{ms}^{-1}$ for *in vivo* protocols), for a total of 1600 synthetic voxels. 697 We corrupted synthetic signals with Rician noise (b = 0 signal-to-noise ratio: 30), and performed 698 model selection according to TCS, HFC and BIC. 699

700

701 <u>dMRI-histology correlation analysis</u>

We computed mean and standard deviation of all metrics i) within the mouse liver samples, ii) within a mask containing all liver tumours in patients, iii) within the biopsied patients' tumours. We pooled together metrics from mice and patients to calculate Pearson's correlation coefficients *r*. In doing so, ADC was normalised to the ADC of the PBS solutions in mice and to the free water diffusivity in patients (3.0 μ m² ms⁻¹ at 37 °C), given the difference in temperature.

- 707
- 708 <u>Response assessment in immunotherapy</u>

We studied mean values of *in vivo* baseline dMRI metrics within liver tumours to assess whether 709 these could stratify the probability of progression under immunotherapy, measured by PFS (N =710 30). Firstly, we performed the stratification after binarising all MRI metrics as lower/higher than 711 the median of the cohort, creating two groups. We evaluated group-wise survival curves with the 712 713 Kaplan-Meier estimator, and compared them with a log-rank test. We also fitted a proportional hazard Cox regression, where the binarised MRI metric was the only regressor. Secondly, we 714 stratified PFS without binarising MRI metrics. We fitted a proportional hazard Cox model using 715 each continous dMRI metric as the only regressor (in the form of a z-score), and then fitted the 716 statistical model again, including age, sex and total baseline tumour volume as confounding 717 factors. We performed all analyses in Python, using lifelines. 718

719

720 Acknowledgments

We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and 721 IT teams at the Vall d'Hebron University Hospital and at the Vall d'Hebron Institute of Oncology 722 in Barcelona (Spain), without whom this study would not have been possible. We are also thankful 723 to the Vall d'Hebron Radiology department and to the ASCIRES CETIR clinical team for their 724 assistance, and to past and present members of the Radiomics group for useful discussion and 725 advice. Finally, we would like to express our sincere gratitude to all patients and their families for 726 dedicating their time to research. VHIO would like to acknowledge: the State Agency for Research 727 (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo 728 Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing 729 research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya 730 for their support on this research. This research has been supported by PREdICT, sponsored by 731 AstraZeneca. This study has been co-funded by the European Regional Development 732 Fund/European Social Fund 'A way to make Europe' (to R.P.L.), and by the Comprehensive 733 734 Program of Cancer Immunotherapy & Immunology (CAIMI), funded by the Banco Bilbao Vizcava Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L is supported by the 735 "la Caixa" Foundation CaixaResearch Advanced Oncology Research Program, the Prostate 736 Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO 737 Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud 738 Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra 739 el Cancer (AECC) (PRYCO211023SERR) and the Generitat de Catalunya Agency for 740 Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The 741 742 project that gave rise to these results received the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010" (funding F.G., 743 A.V., and A.G.) and "LCF/BQ/PI20/11760033" (funding I.C.S). I.C.S. also receives the support 744 of the European Union's Horizon 2020 research and innovation programme under the Marie 745 Sklodowska-Curie grant agreement No 847648. This research has received support from the 746 Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the 747

748 749	Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP
750	00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship
751	MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586).
752	
753	Author information
754	Francesco Grussu and Raquel Perez-Lopez are joint corresponding authors.
755	
756	Authors and affiliations
757 758 759 760	Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. Francesco Grussu, Kinga Bernatowicz, Irene Casanova-Salas, Ignasi Barba, Sara Simonetti, Garazi Serna, Athanasios Grigoriou, Anna Voronova, Rodrigo Toledo, Paolo Nuciforo & Raquel Perez-Lopez.
761	Cardiff University, Cardiff, United Kingdom. Marco Palombo.
762	University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain. Ignasi Barba.
763 764	Department of Biomedicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. Athanasios Grigoriou & Anna Voronova.
765	PET/MR Unit, CETIR-ASCIRES, Barcelona, Spain. Valezka Garay.
766 767	Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Juan Francisco Corral, Xavier Merino, Richard Mast, Núria Roson & Manuel Escobar.
768 769	Institut de Diagnòstic per la Imatge (IDI), Barcelona, Spain. Juan Francisco Corral, Xavier Merino, Richard Mast, Núria Roson & Manuel Escobar.
770	Siemens Healthineers, Madrid, Spain. Marta Vidorreta.
771	GE HealthCare, Madrid, Spain. Pablo García-Polo García.
772	Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute
773	of Oncology (VHIO), Barcelona, Spain. Maria Vieito, Joaquin Mateo & Elena Garralda
774	
775	Contributions
776	Conceptualization: F.G., R.P.L., K.B., M.P., E.G., R.T., P.N., J.M. Methodology: F.G., R.P.L.,
777	K.B., M.P., A.G. Investigation: F.G., R.P.L., K.B., I.C.S., I.B., S.S., G.S., A.G., V.G., J.F.C., X.M.,
778	R.M., N.R., M.E., M.Vie., R.T., P.N., J.M., E.G. Resources: R.P.L., F.G., P.N., J.M., E.G., N.R.,
779	M.E., V.G., M.Vid., P.G.P.G, I.B. Formal analysis: F.G. Visualization: F.G. Software: F.G., K.B.,

- A.G. Data curation: F.G., R.P.L., K.B., A.V., G.S., I.C.S., A.G. Project administration: F.G.,
- 781 R.P.L., K.B., E.G., P.N., R.T., J.M., I.C.S. Funding acquisition: R.P.L., E.G., R.T., P.N., J.M.,

- F.G., K.B., I.C.S. Supervision: F.G., R.P.L., E.G., R.T., P.N., J.M. Writing—original draft: F.G.,
 R.P.L., K.B., M.P. Writing—review & editing: all authors
- 784 **Corresponding authors**
- 785 Correspondence to Francesco Grussu or Raquel Perez-Lopez.
- 786

787 Ethics declarations

788 **Competing interests**

789 This study received funding from AstraZeneca. M.Vid. works for Siemens Healthineers. P.G.P.G. 790 works for GE HealthCare. K.B. worked as a researcher at the Vall d'Hebron Institute of Oncology 791 (Barcelona), and is now an employee of AstraZeneca. AstraZeneca, Siemens and General Electric 792 did not influence the acquisition and analysis of the data, the interpretation of the results, or the 793 decision to submit the manuscript in its current form for publication.

794 Ethics

All experimental protocols in animals were approved and monitored by the Vall d'Hebron Institute of Research Animal Experimentation Ethics Committee (CEEA; registration number 68/20) in accordance with relevant local and EU regulations. The imaging study in cancer patients was approved by the Vall d'Hebron University Hospital Ethics committee (PR(AG)29/2020), Barcelona, Spain. Patients provided informed written consent to participate in the study.

800

801 Supplementary Information

- 802 This article includes Supplementary Figure S1 to S17 and Supplementary Tables S1 to S5.
- 803

804 **References**

- 805
- Weiskopf, N., Edwards, L. J., Helms, G., Mohammadi, S. & Kirilina, E. Quantitative magnetic
 resonance imaging of brain anatomy and in vivo histology. *Nature Reviews Physics* 3, 570–588
 (2021).
- Jarrett, A. M. *et al.* Quantitative magnetic resonance imaging and tumor forecasting of breast cancer
 patients in the community setting. *Nat. Protoc.* 16, 5309–5338 (2021).
- 811 3. Kiselev, V. G. Fundamentals of diffusion MRI physics. *NMR Biomed.* **30**, (2017).
- 4. Novikov, D. S., Fieremans, E., Jespersen, S. N. & Kiselev, V. G. Quantifying brain microstructure
 with diffusion MRI: Theory and parameter estimation. *NMR Biomed.* 32, e3998 (2019).
- 5. Le Bihan, D. Looking into the functional architecture of the brain with diffusion MRI. *Nat. Rev. Neurosci.* 4, 469–480 (2003).
- 816 6. Panagiotaki, E. *et al.* Noninvasive quantification of solid tumor microstructure using VERDICT
 817 MRI. *Cancer Res.* 74, 1902–1912 (2014).

- 818 7. Veraart, J. *et al.* Noninvasive quantification of axon radii using diffusion MRI. *Elife* 9, e49855
 819 (2020).
- 8. Cohen-Adad, J. *et al.* Generic acquisition protocol for quantitative MRI of the spinal cord. *Nat. Protoc.* 16, 4611–4632 (2021).
- Baxter, G. C., Graves, M. J., Gilbert, F. J. & Patterson, A. J. A Meta-analysis of the Diagnostic
 Performance of Diffusion MRI for Breast Lesion Characterization. *Radiology* 291, 632–641 (2019).
- 10. Donato, H., França, M., Candelária, I. & Caseiro-Alves, F. Liver MRI: From basic protocol to
 advanced techniques. *Eur. J. Radiol.* 93, 30–39 (2017).
- Tapper, E. B. & Lok, A. S.-F. Use of Liver Imaging and Biopsy in Clinical Practice. N. Engl. J.
 Med. 377, 756–768 (2017).
- 12. Tsilimigras, D. I. et al. Liver metastases. Nat Rev Dis Primers 7, 27 (2021).
- Eisenhauer, E. A. *et al.* New response evaluation criteria in solid tumours: revised RECIST
 guideline (version 1.1). *Eur. J. Cancer* 45, 228–247 (2009).
- 14. Buikhuisen, J. Y., Torang, A. & Medema, J. P. Exploring and modelling colon cancer inter-tumour
 heterogeneity: opportunities and challenges. *Oncogenesis* 9, 66 (2020).
- 15. Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and
 response to immunotherapy. *Nat. Med.* 27, 212–224 (2021).
- 835 16. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic
 836 science to clinical practice. *Nat. Rev. Immunol.* 20, 651–668 (2020).
- Pilard, C. *et al.* Cancer immunotherapy: it's time to better predict patients' response. *Br. J. Cancer* **125**, 927–938 (2021).
- 18. O'Connor, J. P. B. *et al.* Imaging biomarker roadmap for cancer studies. *Nat. Rev. Clin. Oncol.* 14, 169–186 (2017).
- In Jiang, X., Xu, J. & Gore, J. C. Mapping hepatocyte size in vivo using temporal diffusion
 spectroscopy MRI. *Magn. Reson. Med.* 84, 2671–2683 (2020).
- Panagiotaki, E. *et al.* Microstructural Characterization of Normal and Malignant Human Prostate
 Tissue With Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours Magnetic
 Resonance Imaging. *Invest. Radiol.* 50, 218 (2015).
- 846 21. Gardier, R. *et al.* Cellular Exchange Imaging (CEXI): Evaluation of a diffusion model including
 847 water exchange in cells using numerical phantoms of permeable spheres. *Magn. Reson. Med.* (2023)
 848 doi:10.1002/mrm.29720.
- 849 22. Hoffmann, E. *et al.* Profiling specific cell populations within the inflammatory tumor
 850 microenvironment by oscillating-gradient diffusion-weighted MRI. *J Immunother Cancer* 11,
 851 e006092 (2023).
- 23. Jiang, X. *et al.* MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. *J Immunother Cancer* 8, (2020).
- 24. Ye, Z. et al. Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI)
- and Machine Learning Improves Detection and Classification of Glioblastoma Pathology. *Clin.*
- 856 *Cancer Res.* **26**, 5388–5399 (2020).

857 858	25.	Howard, A. F. <i>et al.</i> Joint modelling of diffusion MRI and microscopy. <i>Neuroimage</i> 201 , 116014 (2019)
850 850	26	Novikov D S. Kisolov V G & Josporson S N On modeling Magn Pason Mod 70 2172 2102
860	20.	(2018)
861	27	Xu I at al Diffusion time dependency of extracellular diffusion Magn Reson Med 89 2432
862	27.	2440 (2023)
863	28	Neuman C H Spin echo of spins diffusing in a bounded medium <i>L Chem Phys</i> 60 4508_4511
863 864	20.	(1974).
865	29.	Conlin, C. C. et al. Improved Characterization of Diffusion in Normal and Cancerous Prostate
866		Tissue Through Optimization of Multicompartmental Signal Models. J. Magn. Reson. Imaging 53,
867		628–639 (2021).
868	30.	Jensen, J. H., Helpern, J. A., Ramani, A. & Lu, H. Diffusional kurtosis imaging: the quantification
869		of non-gaussian water diffusion by means of magnetic resonance imaging. in Medicine: An
870		(2005).
871	31.	Hectors, S. J. et al. Advanced Diffusion-weighted Imaging Modeling for Prostate Cancer
872		Characterization: Correlation with Quantitative Histopathologic Tumor Tissue Composition-A
873		Hypothesis-generating Study. Radiology 286, 918–928 (2018).
874	32.	Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7,
875		16878 (2017).
876	33.	Schwarz, G. Estimating the Dimension of a Model. aos 6, 461–464 (1978).
877	34.	Panagiotaki, E. et al. Compartment models of the diffusion MR signal in brain white matter: a
878		taxonomy and comparison. Neuroimage 59, 2241–2254 (2012).
879	35.	Ferizi, U. et al. A ranking of diffusion MRI compartment models with in vivo human brain data.
880		Magn. Reson. Med. 72, 1785–1792 (2014).
881	36.	Palombo, M. et al. Joint estimation of relaxation and diffusion tissue parameters for prostate cancer
882		with relaxation-VERDICT MRI. Sci. Rep. 13, 2999 (2023).
883	37.	Jiang, X., Devan, S. P., Xie, J., Gore, J. C. & Xu, J. Improving MR cell size imaging by inclusion of
884		transcytolemmal water exchange. NMR Biomed. 35, e4799 (2022).
885	38.	Rosenkrantz, A. B. et al. Assessment of hepatocellular carcinoma using apparent diffusion
886		coefficient and diffusion kurtosis indices: preliminary experience in fresh liver explants. Magn.
887		<i>Reson. Imaging</i> 30 , 1534–1540 (2012).
888	39.	Tang, WJ. et al. Evaluation of the Effects of Anti-PD-1 Therapy on Triple-Negative Breast Cancer
889		in Mice by Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced Imaging. J. Magn. Reson.
890		<i>Imaging</i> 56 , 1912–1923 (2022).
891	40.	Martin, N. C. et al. Functional analysis of mouse hepatocytes differing in DNA content: volume,
892		receptor expression, and effect of IFNgamma. J. Cell. Physiol. 191, 138-144 (2002).
893	41.	Zhou, Z., Xu, MJ. & Gao, B. Hepatocytes: a key cell type for innate immunity. <i>Cell. Mol.</i>
894		<i>Immunol.</i> 13 , 301–315 (2016).

- 42. Grussu, F. *et al.* Diffusion MRI signal cumulants and hepatocyte microstructure at fixed diffusion
 time: Insights from simulations, 9.4T imaging, and histology. *Magn. Reson. Med.* (2022)
 doi:10.1002/mrm.29174.
- 43. Morawski, M. *et al.* Developing 3D microscopy with CLARITY on human brain tissue: Towards a
 tool for informing and validating MRI-based histology. *Neuroimage* 182, 417–428 (2018).
- 44. Jelescu, I. O., Veraart, J., Fieremans, E. & Novikov, D. S. Degeneracy in model parameter
 estimation for multi-compartmental diffusion in neuronal tissue. *NMR Biomed.* 29, 33–47 (2016).
- 45. Nilsson, M. *et al.* Mapping prostatic microscopic anisotropy using linear and spherical b-tensor
 encoding: A preliminary study. *Magn. Reson. Med.* 86, 2025–2033 (2021).
- 46. Fokkinga, E. *et al.* Advanced Diffusion-Weighted MRI for Cancer Microstructure Assessment in
 Body Imaging, and Its Relationship With Histology. *J. Magn. Reson. Imaging* (2023)
 doi:10.1002/jmri.29144.
- 47. Jensen, J. H., Russell Glenn, G. & Helpern, J. A. Fiber ball imaging. *Neuroimage* 124, 824–833
 (2016).
- 48. McKinnon, E. T., Helpern, J. A. & Jensen, J. H. Modeling white matter microstructure with fiber
 ball imaging. *Neuroimage* 176, 11–21 (2018).
- 49. Warner, W. *et al.* Temporal Diffusion Ratio (TDR) for imaging restricted diffusion: Optimisation
 and pre-clinical demonstration. *Neuroimage* 269, 119930 (2023).
- 50. Reynaud, O. Time-Dependent Diffusion MRI in Cancer: Tissue Modeling and Applications.
 Frontiers in Physics 5, (2017).
- 51. Serrablo, A. *et al.* Impact of novel histopathological factors on the outcomes of liver surgery for
 colorectal cancer metastases. *Eur. J. Surg. Oncol.* 42, 1268–1277 (2016).
- 52. Nuciforo, P. *et al.* A predictive model of pathologic response based on tumor cellularity and tumorinfiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual
 HER2 blockade. *Ann. Oncol.* 29, 170–177 (2018).
- 53. Gentile, D. *et al.* Pathologic response and residual tumor cellularity after neo-adjuvant
 chemotherapy predict prognosis in breast cancer patients. *Breast* 69, 323–329 (2023).
- 54. Lee, H.-H., Papaioannou, A., Novikov, D. S. & Fieremans, E. In vivo observation and biophysical
 interpretation of time-dependent diffusion in human cortical gray matter. *Neuroimage* 222, 117054
 (2020).
- 55. Fortin, J.-P. *et al.* Harmonization of multi-site diffusion tensor imaging data. *Neuroimage* 161, 149–
 170 (2017).
- 56. Boonstra, H., Oosterhuis, J. W., Oosterhuis, A. M. & Fleuren, G. J. Cervical tissue shrinkage by
 formaldehyde fixation, paraffin wax embedding, section cutting and mounting. *Virchows Arch. A Pathol. Anat. Histopathol.* 402, 195–201 (1983).
- 57. Xu, J. *et al.* MRI-cytometry: Mapping nonparametric cell size distributions using diffusion MRI.
 Magn. Reson. Med. 85, 748–761 (2021).
- 58. Xu, J. *et al.* Magnetic resonance imaging of mean cell size in human breast tumors. *Magn. Reson. Med.* 83, 2002–2014 (2020).

- 59. Reynaud, O. *et al.* Pulsed and oscillating gradient MRI for assessment of cell size and extracellular
 space (POMACE) in mouse gliomas. *NMR Biomed.* 29, 1350–1363 (2016).
- 60. Le Bihan, D. *et al.* MR imaging of intravoxel incoherent motions: application to diffusion and
 perfusion in neurologic disorders. *Radiology* 161, 401–407 (1986).
- 61. Li, Y. T. *et al.* Liver intravoxel incoherent motion (IVIM) magnetic resonance imaging: a
 comprehensive review of published data on normal values and applications for fibrosis and tumor
 evaluation. *Quant. Imaging Med. Surg.* 7, 59–78 (2017).
- 62. Balinov, B., Jonsson, B., Linse, P. & Soderman, O. The NMR Self-Diffusion Method Applied to
 Restricted Diffusion. Simulation of Echo Attenuation from Molecules in Spheres and between
 Planes. J. Magn. Reson. A 104, 17–25 (1993).
- 63. Veraart, J. *et al.* Denoising of diffusion MRI using random matrix theory. *Neuroimage* 142, 394–406 (2016).
- 64. Kellner, E., Dhital, B., Kiselev, V. G. & Reisert, M. Gibbs-ringing artifact removal based on local
 subvoxel-shifts. *Magn. Reson. Med.* 76, 1574–1581 (2016).
- 65. Jerome, N. P. *et al.* Extended T2-IVIM model for correction of TE dependence of pseudo-diffusion
 volume fraction in clinical diffusion-weighted magnetic resonance imaging. *Phys. Med. Biol.* 61,
 N667–N680 (2016).
- 66. Garyfallidis, E. *et al.* Dipy, a library for the analysis of diffusion MRI data. *Front. Neuroinform.* 8, 8
 (2014).
- 67. Ourselin, S., Roche, A., Subsol, G., Pennec, X. & Ayache, N. Reconstructing a 3D structure from
 serial histological sections. *Image Vis. Comput.* 19, 25–31 (2001).
- 68. Andersson, J. L. R., Skare, S. & Ashburner, J. How to correct susceptibility distortions in spin-echo
 echo-planar images: application to diffusion tensor imaging. *Neuroimage* 20, 870–888 (2003).
- 69. Avants, B. B., Epstein, C. L., Grossman, M. & Gee, J. C. Symmetric diffeomorphic image
 registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative
 brain. *Med. Image Anal.* 12, 26–41 (2008).
- 70. Rafael-Patino, J. *et al.* Robust Monte-Carlo Simulations in Diffusion-MRI: Effect of the Substrate
 Complexity and Parameter Choice on the Reproducibility of Results. *Front. Neuroinform.* 14, 8
 (2020).
- 963
- 964
- 965
- 966
- 967
- 968
- 969

970 Figures



971

Fig. 1. Illustration of the liver MRI and histology data used in the study. Our data set consisted 972 973 of preclinical and clinical data. The preclinical data encompasses dMRI scans of seven fixed livers from mice (six implanted with tissue from biopsies of patients suffering from prostate cancer; one 974 without any implantation). We scanned the livers ex vivo on a 9.4T system, and obtained HE 975 histological sections at known position. The clinical data includes in vivo liver dMRI scans 976 performed on 33 patients suffering from advanced liver tumours. Scans were performed on clinical 977 1.5T and 3T MRI systems. For 18 patients, HE-stained material from a biopsy taken from one of 978 the imaged liver tumours was also available. 30 out of 33 patients effectively participated in a 979 phase I immunotherapy trial, and clinical outcome was available as PFS. We used a total sample 980 size of N = 25 for dMRI model design and of N = 30 for response assessment. In the figure, PC 981 982 standard fort prostate cancer and HCC for hepatocellular carcinoma.



983

Fig. 2. Description of the dMRI signal models and study overview. (A), top: cartoon illustrating 984 the two families of dMRI models considered in this study, consisting of 1) models with no 985 assumption of which of intra/extra-cellular ADC is higher, and 2) models where the extra-cellular 986 ADC is hypothesised to be higher than the intra-cellular ADC. (B), bottom: study overview. We 987 analysed dMRI data from fixed mouse livers (preclinical data) and from cancer patients imaged in 988 vivo (clinical data) to derive estimates of intra-cellular fraction and of cell size. In parallel, we 989 processed histological material from the same tissues (whole-liver sections for the preclinical 990 mouse data; biopsies from one of the imaged tumours for the clinical data), and derived the 991 histological counterparts of such dMRI metrics. We compared dMRI and histological cell size and 992

intra-cellular fraction to select the dMRI model featuring the best fidelity to histology. The utility 993 of the model was then demonstrated in immunotherapy response assessment in vivo. In Fig. 2, 994 pictures from Servier Medical Art have been used. Servier Medical Art by Servier is licensed under 995 Creative Commons Attribution 3.0 Unported License 996 а 997 (https://creativecommons.org/licenses/by/3.0).

- 998
- 999
- 1000
- 1001



1002 1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

Fig. 3. Biophysical dMRI signal model selection based on the MRI-histology Total Correlation Score (TCS). (A): panel summarising the salient differences between the biophysical dMRI models compared in this study. Models can be divided in two families, i.e.: i) models where it is hypothesised that the extra-cellular ADC is higher than the intra-cellular ADC, and ii) models with no hypothesis on which, between intra-/extra-cellular ADC is higher. Violet shades are used for the first family (models Diff-in, Diff-in-exFast and Diff-in-exTDFast), while orange shades for the second family (models *Diff-in-ex* and *Diff-in-exTD*). (B): values of TCS for all models, as obtained by fitting them on high b-value images ($b > 1800 \text{ s/mm}^2$ in the fixed mouse livers; $b > 1800 \text{ s/mm}^2$ 900 s/mm² in vivo). We performed model selection using a sample size of N = 25 (see Fig. 1). In Fig. 3, pictures from Servier Medical Art have been used. Servier Medical Art by Servier is licensed under а Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0).





Fig. 4. Maps from the selected dMRI model *Diff-in* with their histological counterparts in the 1016 fixed mouse livers scanned at 9.4T ex vivo. The figure reports MRI and histology data for 3 1017 specimens, representative of the 3 microstructural phenotypes observed in our ex vivo data set, 1018 namely: normal liver structures (Control case); a proliferative process, characterized by infiltration 1019 of small cells (Patinfl case); necrosis and inflammation (Patnec case). For all specimens, the 1020 following is shown. (A), top left: a high-resolution T2-w anatomical scan is shown next to the 1021 corresponding HE section, with histological details. (B), bottom left: histological maps warped to 1022 the dMRI space (intra-cellular patch area fraction F_{histo} ; volume-weighted mean cell size index 1023 vCS_{histo} ; cell density per unit patch area CD_{histo}). (D), bottom right: dMRI maps F_{MRI} , vCS_{MRI} 1024

and CD_{MRI} from the selected dMRI signal model (model Diff-in, fitted to high b-value images, i.e., 1025 $b > 1800 \text{ s/mm}^2$). 1026

- 1027
- 1028
- 1029



1030

1031 Fig. 5. Examples of maps from the proposed dMRI model Diff-in in liver tumours of patients scanned at 1.5T and 3T in vivo, with co-localised biopsies. MRI maps are shown in a biopsied 1032 liver tumour in two patients for each MRI scanner, arranged along rows. (A): examples of slices 1033 from the high-resolution anatomical T2-w image and from a high b-value image, with biopsied 1034 tumour outlined. (C): maps from the selected model (*Diff-in*, fitted to high b-value images b > 9001035 s/mm²). From left to right: intra-cellular signal fraction F_{MRI}; volume-weighted mean cell size 1036 index vCS_{MRI} ; cell density per unit volume CD_{MRI} . (C): histological details from the HE-stained 1037 biopsy. For the 1.5T Siemens scanner (first and second rows from top) we report: patient 6 1038 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 1039 3T GE scanner (third and fourth rows from top) we report: patient 24 (primary hepatocellular 1040 carcinoma (HCC)) and patient 30 (liver metastases from breast cancer). 1041

1042



1043

Fig. 6. Immunotherapy response assessment based on metrics from the proposed model Diff-1044 in within liver tumours at baseline. This figure reports on the dependence of patients' 1045 progression-free survival (PFS) on the average value of F, vCS and CD within liver tumours at 1046 baseline (i.e., before starting immunotherapy), as obtained by fitting model *Diff-in* at high b-value. 1047 Left: Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on 1048 baseline F (panel A), vCS (panel C) and CD (panel D) (lower/higher than the sample median). The 1049 grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox 1050 regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate 1051

and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and 1052 Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. *Right:* results from 1053 univariate Cox regression where the baseline F (panel B), νCS (panel D) and CD (panel F) is a 1054 continuous predictor of the survival. The panel shows how changes in baseline F, vCS and CD1055 modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value 1056 and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-1057 axis shows 1 - p, with p being the probability of progression, while the x-axis shows the time to 1058 1059 progression (in days). We performed the response assessment using a sample size of N = 30 (Fig. 1). 1060





1062

1063Fig. 7. Immunotherapy response assessment based on mean ADC and kurtosis K within liver1064tumours at baseline. This figure reports on the dependence of patients' progression-free survival1065(PFS) on the average value of ADC and K within liver tumours at baseline (i.e., before starting1066immunotherapy). Left: Kaplan-Meier (KM) survival curves of two groups obtained by splitting1067patients based on baseline ADC (panel A) and K (panel C) (lower/higher than the sample median).

The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox 1068 regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate 1069 and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and 1070 Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. Right: results from 1071 1072 univariate Cox regression where the baseline ADC (panel B) and K (panel D) is a continuous predictor of the survival. The panel shows how changes in baseline ADC and K modulate the 1073 survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 1074 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows 1 1075 -p, with p being the probability of progression, while the x-axis shows the time to progression (in 1076 days). We performed the response assessment using a sample size of N = 30 (Fig. 1). 1077

1078

1079 Tables

1080	Table 1. Correlation between dMRI metrics and histological metrics. The table reports
1081	Pearson's correlation coefficients r and corresponding p-values p of dMRI metrics F_{MRI} (intra-
1082	cellular fraction), vCS_{MRI} (volume-weighted cell size index) and CD_{MRI} (cell density per unit
1083	volume) with their histological pairs (F_{histo} , vCS_{histo} and CD_{histo} respectively) for the selected
1084	dMRI model (Diff-in, fitted to high b-value images). The table also reports correlation coefficients
1085	between routine ADC and K from DKI and each of F_{histo} , vCS_{histo} and CD_{histo} . The sample size
1086	was N = 25, so that $p < 0.05$ if $ r > 0.3961$. When $p < 0.05$, grey shadowing is used.

dMRI technique	Histology F _{histo}	Histology <i>vCS_{histo}</i>	Histology CD _{histo}
Model	With F_{MRI} :	With vCS_{MRI} :	With <i>CD_{MRI}</i> :
Diff-in	r = 0.19; p = 0.37	r = 0.44; p = 0.029	r = 0.70; p = 0.0001
	With ADC:	With ADC:	With ADC:
Routine	r = -0.28; p = 0.18	r = 0.49; p = 0.014	r = -0.47; p = 0.017
DKI	With <i>K</i> :	With <i>K</i> :	With <i>K</i> :
	r = 0.40; p = 0.048	r = -0.31; p = 0.13	r = 0.43; p = 0.033

1087

Supplementary Information for

Histology-informed liver diffusion MRI: biophysical model design and demonstration in cancer immunotherapy

Francesco Grussu*, Kinga Bernatowicz, Marco Palombo, Irene Casanova-Salas, Ignasi Barba, Sara Simonetti, Garazi Serna, Athanasios Grigoriou, Anna Voronova, Valezka Garay, Juan Francisco Corral, Marta Vidorreta, Pablo García-Polo García, Xavier Merino, Richard Mast, Núria Roson, Manuel Escobar, Maria Vieito, Rodrigo Toledo, Paolo Nuciforo, Joaquin Mateo, Elena Garralda, Raquel Perez-Lopez*

*Corresponding authors: Francesco Grussu, email: fgrussu@vhio.net, Raquel Perez-Lopez, email: rperez@vhio.net

Table of contents

Supplementary Fig. S1: radiological-histological co-localisation of the ex vivo mouse liver data. **Supplementary Fig. S2:** MRI-histology Total Correlation Score (TCS) for biophysical dMRI model selection, as obtained when fitting dMRI signal models on the whole image set.

Supplementary Fig. S3: biophysical dMRI signal model selection based on BIC and HFC criteria. **Supplementary Fig. S4:** biophysical model selection across different MRI scanners and data subsets.

Supplementary Fig. S5: environments used to generate synthetic dMRI signals in computer simulations.

Supplementary Fig. S6: MRI-histology correlations for models with no assumptions on which is larger between intra-cellular and extra-cellular ADC.

Supplementary Fig. S7: MRI-histology correlations for models where the extra-cellular ADC is constrained to be larger than the intra-cellular ADC.

Supplementary Fig. S8: standard diffusion MRI metrics in fixed mouse livers ex vivo.

Supplementary Fig. S9: key parametric maps of the *Diff-in-exFast* model on *ex vivo* mouse livers. **Supplementary Fig. S10:** diffusivity metrics from biophysical MRI models in fixed *ex vivo* mouse livers.

Supplementary Fig. S11: standard diffusion MRI metrics in patients in vivo.

Supplementary Fig. S12: key parametric maps of the Diff-in-exFast model in patients in vivo.

Supplementary Fig. S13: diffusivity metrics from biophysical MRI models in patients in vivo.

Supplementary Fig. S14: immunotherapy response assessment based on *Diff-in* cytosol diffusivity estimates.

Supplementary Fig. S15: immunotherapy response assessment based on vascular fraction estimates.

Supplementary Fig. S16: immunotherapy response assessment based on *Diff-in-exFast* MRI metrics.

Supplementary Fig. S17: schematic of the dMRI sequences used in this study.

Supplementary Table S1: results of the model selection based on the Total Correlation Score (TCS) as obtained on simulated dMRI signals.

Supplementary Table S2: results of the model selection based on the Histology Fidelity Criterion (HFC) as obtained on simulated dMRI signals.

Supplementary Table S3: results of the model selection based on the Bayesian Information Criterion (BIC) as obtained on simulated dMRI signals.

Supplementary Table S4: descriptive statistics of histology and MRI metrics in the fixed mouse livers.

Supplementary Table S5: hazard ratios obtained from Cox regression models controlling for sex, age, and baseline tumour volume.



Fig. S1: radiological-histological co-localisation of the ex vivo mouse liver data.

Illustration of the radiological-histological co-localisation on the 7 fixed mouse livers obtained from mice implanted with a biopsy from a prostate cancer patient. (A), left: illustrative slice of the high-resolution anatomical T2-weighted fast spin echo. (B), centre: hematoxylin and eosin (HE)stained section, taken from the MRI slice shown to the left. (C), right: detail of the microstructure characterising each specimen, as assessed by an experienced pathologist (SS). Different specimens are arranged along different rows. From top to bottom: *Control*, normal liver structures (no biopsy implantation); Pat_{NA1} and Pat_{NA2} , normal appearing normal liver structures after prostate cancer biopsy implantation; Pat_{inf1} , Pat_{inf2} and Pat_{inf3} : pathology following implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces); Pat_{nec} , pathology following implantation, consisting of necrosis and inflammation.



Fig. S2: MRI-histology Total Correlation Score (TCS) for biophysical dMRI model selection, as obtained when fitting dMRI signal models on the whole image set.

Values of TCS for all models, as obtained by fitting models on the whole image set (set of images with negligible vascular signal contributions, i.e., b > 1000 s/mm² in the fixed mouse livers and b > 100 s/mm² *in vivo*). We evaluated TCS for histology-informed model selection using a sample size of N = 25.



Fig. S3: biophysical dMRI signal model selection based on BIC and HFC criteria.

Frequency of model selection based on the *Bayesian Information Criterion* (BIC, quantifying how well a model fits the dMRI signals, penalising model complexity) and on the *Histology-fidelity Criterion* (HFC, quantifying how accurately a dMRI models estimates the intra-cellular fraction and the volume-weighted cell size as seen on histology). (A) reports results when models are fitted to the entire set of measurements with negligible vascular signal constributions ($b > 1000 \text{ s/mm}^2$ for suppression of PBS fluid within vessels in the fixed mouse livers; $b > 100 \text{ s/mm}^2$ for IVIM signal suppression *in vivo* on clinical systems), while (**B**) reporting results obtained when fitting models only on high b-value images ($b > 1800 \text{ s/mm}^2$ in the fixed mouse livers; $b > 900 \text{ s/mm}^2$ *in vivo*).





Frequency of selection of each of 5 biophysical dMRI models on 3 MRI-histology data subsets. First column: selection on 7 fixed mouse livers scanned ex vivo on a preclinical 9.4T Bruker system (A and D, left); Second column: selection on 6 liver tumours imaged *in vivo* on a clinical 1.5T Siemens system (B and E, middle); Third column: selection on 12 liver tumours imaged in vivo on a clinical 3T GE system (C and F, right). Plots on top (A to C) refer to dMRI model fitting performed on images where the vascular signal was suppressed ("whole image set fitting", b >1000 s/mm² for suppression of PBS fluid within vessels on the 9.4T; b > 100 s/mm² for IVIM signal suppression on clinical systems). Plots to the bottom (D to F) refer to dMRI model fitting performed on images where both vascular and extra-cellular, extra-vascular signals were suppressed ("high b-value fitting", b > 1800 s/mm² on the 9.4T; b > 900 s/mm² on clinical systems). Violet: models where extra-cellular ADC is larger than intra-cellular ADC; orange: models with no constraints on which is larger between intra-/extra-cellular ADC. The Bayesian Information Criterion (BIC) selects a model depending on the goodness of MRI signal fitting. The Histology Fidelity Criterion (HFC) selects a model depending on the overall agreement between MRI volume-weighted Cell Size (vCS) and intra-cellular fraction (F) with their histology counterparts.



Fig. S5: environments used to generate synthetic dMRI signals in computer simulations.

The synthetic environment consisted of meshed spheres of fixed diameter, representing cells, as this is a common biophysical model used in several dMRI techniques (e.g., VERDICT, IMPULSED). We used the synthetic environment to generate dMRI signals via Monte Carlo simulations for each of the 3 dMRI protocols considered in this study (the PGSE protocol used on the ex vivo mouse livers at 9.4T; the PGSE protocol used in patients in vivo at 3T; the DW TRSE protocol used in patients in vivo at 1.5T). Afterwards, we performed performed dMRI model selection on the synthetic signals, following the same procedures implemented for actual ex vivo and *in vivo* dMRI data. We controlled the intra-sphere fraction F by adding gaps of increasing size in-between abutting spheres packed in an ideal cubic lattice. We probed 4 different values of F(approximately equal to 0.197, 0.323, 0.406, 0.523; notice that the maximum theoretical value of F for cubic lattice packing is equal to 0.5236). For each value of F, we varied the cell diameter (8, 16, 22 and 30 μ m), intra-sphere diffusivity (10 linearly-spaced values in the ranges [0.8; 2.6] μ m² ms^{-1} and [0.8; 3.0] $\mu m^2 ms^{-1}$ for the *ex vivo* and *in vivo* protocols respectively) and extra-sphere intrinsic diffusivity (again, 10 linearly-spaced values in the ranges $[0.8; 2.6] \mu m^2 m s^{-1}$ and [0.8;3.0] μ m² ms⁻¹ for the *ex vivo* and *in vivo* protocols respectively), generating a total of 1600 synthetic voxels. Before dMRI signal model fitting, we corrupted synthetic signal with Rician noise at a signal-to-noise ratio (SNR) of 30 on the b = 0 signal s(b=0) (SNR = $s(b=0)/\sigma$, where σ is the noise standard deviation).



Model fitting on whole image set Model fitting on high *b*-value images

Fig. S6: MRI-histology correlations for models with no assumptions on which is larger between intra-cellular and extra-cellular ADC. Matrices illustrating Pearson's correlation coefficients among all possible pairs of MRI and histology metrics. Histological metrics are: intracellular area fraction F_{histo} ; volume-weighted mean cell size index vCS_{histo} ; cell density per unit area CD_{histo} . MRI metrics are: apparent diffusion coefficient ADC; apparent diffusion excess kurtosis K; intra-cellular area fraction F_{MRI} ; volume-weighted mean cell size index vCS_{MRI} ; cell density per unit area CD_{MRI} . Metrics F_{MRI} , vCS_{MRI} and CD_{MRI} were obtained by fitting models with no assumptions on which is larger between intra-cellular and extra-cellular ADC (*Diff-in-ex* and *Diff-in-exTD*). The 4 panels refer to models *Diff-in-ex* and *Diff-in-exTD* fitted according to 2 different strategies. Panel (A): model *Diff-in-ex* fitted on the whole set of measurements with vascular signal suppression (b > 100 s/mm² *in vivo*, b > 1000 s/mm² *ex vivo*); panel (B): model *Diff-in-ex* fitted on high b-value measurements (b > 900 s/mm² *in vivo*, b > 1800 s/mm² *ex vivo*); panel (C): model *Diff-in-exTD* fitted on the whole set of measurements. We calculated correlation coefficients using a sample size of N = 25 (Fig. 1).



Model fitting on whole image set Model fitting on high *b*-value images

Fig. S7: MRI-histology correlations for models where the extra-cellular ADC is constrained to be larger than the intra-cellular ADC. Matrices illustrating Pearson's correlation coefficients among all possible pairs of MRI and histology metrics. Histological metrics are: intra-cellular area fraction F_{histo} ; volume-weighted mean cell size index vCS_{histo} ; cell density per unit area CD_{histo} . MRI metrics are: apparent diffusion coefficient ADC; apparent diffusion excess kurtosis K; intracellular area fraction F_{MRI} ; volume-weighted mean cell size index vCS_{MRI} ; cell density per unit area CD_{MRI} . Metrics F_{MRI} , vCS_{MRI} and CD_{MRI} were obtained by fitting models that assume that the extra-cellular ADC is always larger than the intra-cellular ADC (*Diff-in, Diff-in-exFast* and *Diff-in-exTDFast*). The 6 panels refer to models *Diff-in, Diff-in-exFast* and *Diff-in-exTDFast* fitted

according to 2 different strategies. Panel (**A**): model *Diff-in* fitted on the whole set of measurements with vascular signal suppression ($b > 100 \text{ s/mm}^2$ in vivo, $b > 1000 \text{ s/mm}^2$ ex vivo); panel (**B**): model *Diff-in* fitted on high b-value measurements ($b > 900 \text{ s/mm}^2$ in vivo, $b > 1800 \text{ s/mm}^2$ ex vivo); panel (**C**): model *Diff-in-exFast* fitted on the whole set of measurements with vascular signal suppression; panel (**D**): model *Diff-in-exFast* fitted on high b-value measurements; panel (**E**): model *Diff-in-exTDFast* fitted on the whole set of measurements with vascular signal suppression; panel (**F**): model *Diff-in-exTDFast* fitted on high b-value measurements. We calculated correlation coefficients using a sample size of N = 25 (Fig. 1).



Fig. S8: standard diffusion MRI metrics in fixed mouse livers ex vivo.

(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): standard diffusion metrics, namely ADC (apparent diffusion coefficient) and K (apparent diffusion kurtosis excess). These metrics were obtained by fitting the standard diffusion kurtosis signal representation $s = s_0 \exp(-b ADC + K (b ADC)^2/6)$ to the set of measurements at fixed TE = 45 ms and $\Delta = 30$ ms. From top to bottom, the figure reports maps from 3 specimens, representative of the 3 different microstructural phenotypes seen in our mouse liver data. These are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Patinf*); pathology following biopsy implantation, consisting of necrosis and inflammation (illustrated by case *Patnec*).





(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): metrics from the *Diff-in-exFast* model fitted to the whole DW image set (b-values with negligible vascular signal contributions, i.e., $b > 1000 \text{ s/mm}^2$ on fixed *ex vivo* tissue, to suppress signal from PBS-filled vessels). From left to right: intra-cellular signal fraction F_{MRI} ; volume-weighted cell size index vCS_{MRI} index; cell density per unit volume CD_{MRI} . Maps from 3 specimens are reported along different rows. The specimens are representative of the 3 different microstructural phenotypes seen in our mouse liver data. From top to bottom, these are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case Pat_{inf}); pathology following biopsy implantation, consisting of an inflammation (illustrated by case Pat_{nec}).



Fig. S10: diffusivity metrics from biophysical MRI models in fixed ex vivo mouse livers.

(A): high-resolution fast spin echo scan acquired in fixed mouse livers scanned *ex vivo* on the 9.4T Bruker system. (B): diffusivity metrics from biophysical model *Diff-in-exFast*, namely: intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$; asymptotic extra-cellular diffusion coefficient $D_{E,\infty}$. (C): intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$ from model *Diff-in* fitted to high b-value images $(b > 1800 \text{ s/mm}^2)$. Maps from 3 specimens are reported along different rows. The specimens are representative of the 3 different microstructural phenotypes seen in our mouse liver data. From top to bottom, these are: normal liver structures (illustrated by the *Control* case, e.g., mouse with no biopsy implantation); pathology following biopsy implantation, consisting of an immature, lympho-proliferative process (infiltration of small cells in sinusoidal spaces, illustrated by case *Patinf*); pathology following biopsy implantation, consisting of extended necrosis and inflammation (illustrated by case *Patinec*).



Fig. S11: standard diffusion MRI metrics in patients in vivo.

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): standard diffusion metrics in the biopsied tumour. Metrics are: apparent diffusion coefficient (*ADC*) and apparent diffusion kurtosis excess (*K*). These were obtained by fitting the standard diffusion kurtosis signal representation $s = s_0 \exp(-b ADC + K (b ADC)^2/6)$ to the set of measurements at fixed, minimum TE and $b > 100 \text{ s/mm}^2$. Maps are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (third and fourth rows from top): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).



Fig. S12: key parametric maps of the Diff-in-exFast model in patients in vivo.

(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): salient metrics of the *Diff-in-exFast* model fitted to the whole set of images with negligible vascular signal contributions ($b > 100 \text{ s/mm}^2$). Metrics are shown in the biopsied tumour. From left to right: intra-cellular signal fraction F_{MRI} ; volume-weighted cell size index vCS_{MRI} index; cell density per unit volume CD_{MRI} . Metrics are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (first and second rows from bottom): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).





(A): high-resolution fast spin echo scan as well as a high b-value diffusion image, with biopsied tumour outlined. (B): diffusivity maps from biophysical model *Diff-in-exFast* in the biopsied tumour. Metrics are: intra-cellular cytosolic diffusivity $D_{0,I}$ and asymptotic extra-cellular diffusion coefficient $D_{E,\infty}$. (C): intra-cellular cytosolic diffusivity $D_{0,I}$ for biophysical model *Diff-in* fitted being fitted only to high b-value images (b > 900 s/mm²). Metrics are shown in four representative patients (two patients for each MRI scanner), along different rows. For the 1.5T Siemens scanner (first and second rows from top): patient 6 (primary hepatocellular carcinoma) and patient 3 (liver metastases from ovarian cancer). For the 3T GE scanner (first and second rows from bottom): patient 24 (primary hepatocellular carcinoma) and patient 30 (liver metastases from breast cancer).



Fig. S14: immunotherapy response assessment based on *Diff-in* cytosol diffusivity estimates.

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of the intrinsic intra-cellular cytosol diffusivity $D_{0,I}$ within liver tumours at baseline (i.e., before starting immunotherapy), as obtained by fitting model *Diff-in* at high b-value. Left (panel **A**): Kaplan-Meier (KM) survival curves of two groups obtained by splitting patients based on baseline $D_{0,I}$ (lower or higher than the sample median). The grey panel reports the p-values of a log-rank sum test comparing the KM curves, and of a Cox regression based on the binarised MRI metric (with the corresponding hazard ratio (HR) estimate and 95% confidence interval). The legend reports the Restricted Mean Survival Time (RMST) and Restricted Standard Deviation of Survival Time (RSDST) for each KM curve. Right (panel **B**): results from univariate Cox regression where the baseline $D_{0,I}$ is a continuous predictor of the survival. The panel shows how changes in baseline $D_{0,I}$ modulate the survival curve, given the HR estimated for each metric. In the grey box, the p-value and HR (with 95% CI) corresponding to the baseline MRI metric are reported. In all panels, the y-axis shows 1 - p, with *p* being the probability of progression, while the x-axis shows the time to progression (in days).



Fig. S15: immunotherapy response assessment based on vascular fraction estimates.

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of the vascular signal fraction f_v within liver tumours at baseline (i.e., before starting immunotherapy). The vascular signal fraction f_v was computed in the initial fitting step, which disentangles the vascular from the non-vascular (tissue) signal, before the latter is split into intra-/extra-cellular contributions in the biophysical model fitting step. The same representation layout as in Fig. S6 was used. Left (A): Kaplan-Meier (KM) analysis, log-rank sum test and Cox regression based on the binarised f_v (higher/lower than the sample median). Right (B): Cox regression modelling the probability of survival as a continuous function of baseline f_v . In all panels, the y-axis shows 1 - p, with p being the probability of progression, while the x-axis shows the time to progression (in days).



Fig. S16: immunotherapy response assessment based on Diff-in-exFast MRI metrics.

This figure reports on the dependence of patients' progression-free survival (PFS) on the average value of all *Diff-in-exFast* metrics within liver tumours at baseline (i.e., before starting immunotherapy). In each row, from top to bottom: PFS based on baseline volume-weighted Cell Size vCS (panels A and B), Cell Density *CD* (panels C and D), intra-cellular fraction *F* (panels E

and **F**), intrinsic intra-cellular cytosol diffusivity $D_{0,I}$ (panels **G** and **H**), asymptotic extra-cellular diffusion coefficient $D_{E,\infty}$ (panels **I** and **J**). The same representation layout as in Fig. S6 was used. Left (**A**, **C**, **E**, **G**, **I**): Kaplan-Meier (KM) analysis, log-rank sum test and Cox regression based on the binarised MRI metrics (higher/lower than the sample median). Right (**B**, **D**, **F**, **H**, **J**): Cox regression modelling the probability of survival as a continuous function of baseline MRI metrics. In all panels, the y-axis shows 1 - p, with *p* being the probability of progression, while the x-axis shows the time to progression (in days).



Fig. S17: schematic of the dMRI sequences used in this study.

(A): pulsed gradient spin echo (PGSE sequence, also known as Stejskal-Tanner sequence, pulsedfield gradient (PFG), or single linear diffusion encoding) used to acquire data on the 9.4T Bruker system on fixed mouse livers *ex vivo* and on the 3T GE system on patients *in vivo*. δ and Δ respectively indicate the diffusion gradient duration and separation, while TE is the echo time. (**B**): twice-refocussed diffusion-weighted spin echo sequence used to acquire data on the 1.5T Siemens system on patients *in vivo*. δ_n and $\Delta_{n,m}$ respectively indicate the duration of the *n*-th gradient lobe and the separation time between the *n*-th and *m*-th gradient lobes, for n, m = 1, ..., 4. TE is again the echo time. In both panels, "Signal readout" corresponds to sampling the center of the k-space (i.e., zero spatial frequency).

Table S1: results of the model selection based on the Total Correlation Score (TCS) as obtained on simulated dMRI signals.

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals ("Regular fit": fitting on all b-values with negligible vascular contributions; "High *b* only fit": fitting on b-values minimising extra-cellular signal contributions). The Table reports the value of $TCS = r(vCS_{est}, vCS_{gt}) + r(F_{est}, F_{gt})$, where vCS is the cell size, *F* the intra-cellular fraction, r(x,y) the Pearson's correlation between variables *x* and *y* computed pooling together all synthetic voxels, and where subscripts *est* and *gt* respectively indicate estimated and ground truth values. Higher values of TCS point towards better model performance. For each protocol and fitting strategy, the model with the highest *TCS* is flagged by gray shadowing and bold font.

	Prote ex t	ocol: vivo	Protocol: in vivo PGSE		Prote in vive	ocol: TRSE
	Regular	High b	Regular	High b	Regular	High b
	fit	only fit	fit	only fit	fit	only fit
Maria I.						
Model						
Diff-in-exTD	0.217	-0.111	0.312	0.202	0.604	0.483
Diff-in-ex	0.406	0.089	0.472	0.335	0.700	0.550
Diff-in-exTDFast	0.948	0.827	0.536	0.336	0.618	0.544
Diff-in-exFast	0.952	0.850	0.563	0.349	0.626	0.547
Diff-in	1.222	0.977	0.773	0.462	0.543	0.630

Table S2: results of the model selection based on the Histology Fidelity Criterion (HFC) as obtained on simulated dMRI signals.

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals ("Regular fit": fitting on all b-values with negligible vascular contributions; "High *b* only fit": fitting on b-values minimising extra-cellular signal contributions). For each model, the table reports the percentage of synthetic voxels where $HFC = |vCS_{est} - vCS_{gt}|/vCS_{gt} + |F_{est} - F_{gt}|/F_{gt}$ was the lowest across all models. Above, *vCS* is the cell size, *F* the intra-cellular fraction, and subscripts *est* and *gt* respectively indicate estimated and ground truth values. Higher percentages indicate smaller estimation errors, and therefore point towards better model performance. For each protocol and fitting strategy, the model with the highest proportion of synthetic voxels with minimum HFC is flagged by gray shadowing and bold font.

	Prote ex v	Protocol: ex vivo		ocol: PGSE	Protocol: in vivo TRSE	
	Regular	High b	Regular	High b	Regular	High b
	fit	only fit	fit	only fit	fit	only fit
Madal						
wodei						
Diff-in-exTD	12.62%	13.56%	21.69%	22.10%	26.69%	20.69%
Diff-in-ex	21.19%	16.62%	25.94%	20.35%	28.94%	24.31%
Diff-in-exTDFast	15.50%	14.94%	10.75%	12.27%	19.69%	14.69%
Diff-in-exFast	21.81%	10.50%	22.25%	11.33%	19.12%	12.12%
Diff-in	28.88%	44.38%	19.38%	33.94%	5.56%	28.19%

Table S3: results of the model selection based on the Bayesian Information Criterion (BIC) as obtained on simulated dMRI signals.

We performed model selection on synthetic signals simulated for all the dMRI protocols considered in this study (*ex vivo* PGSE, used on fixed mouse livers; *in vivo* PGSE and DW TRSE, used in patients *in vivo*; see Methods for a full description of the protocols). We fitted the models on protocol subsets obtained with the same b-value thresholds used when analysing actual MRI signals ("Regular fit": fitting on all b-values with negligible vascular contributions; "High *b* only fit": fitting on b-values minimising extra-cellular signal contributions). For each model, the table reports the percentage of synthetic voxels where the Bayesian Information Criterion (BIC, a standard metric of model fitting quality that penalises model complexity) was the lowest across all models. Higher percentages indicate smaller BIC values across synthetic voxels, and therefore point towards better model fitting quality. For each protocol and fitting strategy, the model with the highest proportion of synthetic voxels with minimum HFC is flagged by gray shadowing and bold font.

	Protocol: ex vivo		Protocol: in vivo PGSE		Protocol: in vivo TRSE		
	Regular	High <i>b</i>	Regular	High <i>b</i>	Regular	High <i>b</i>	
	fit	only fit	fit	only fit	fit	only fit	
Model							
Diff-in-exTD	0.12%	0.00%	0.00%	0.19%	0.00%	0.00%	
Diff-in-ex	31.25%	15.88%	17.44%	4.69%	40.69%	13.69%	
Diff-in-exTDFast	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Diff-in-exFast	3.44%	0.06%	6.69%	0.00%	21.38%	1.06%	
Diff-in	65.19%	84.06%	75.88%	95.12%	38.00%	85.25%	

Table S4: descriptive statistics of histology and MRI metrics in the fixed mouse livers.

The table reports mean and standard deviation (within brackets) of histology and dMRI metrics in the 7 fixed mouse livers that were scanned on a 9.4T Bruker system. Histological maps were computed within patches matching the in-plane MRI resolution and then warped non-linearly to dMRI space. The histological maps are: per-patch intra-cellular area fraction F_{histo} , per-patch arithmetic mean cell size aCS_{histo} ; per-patch volume-weighted mean cell size vCS_{histo} , cell density per unit patch area CD_{histo} . dMRI metrics are: apparent diffusion coefficient ADC, apparent diffusion kurtosis excess K, intra-cellular signal fraction F_{MRI} , volume-weighted cell size index vCS_{MRI} , apparent cell density per unit volume CD_{MRI} . Metrics F_{MRI} , vCS_{MRI} and CD_{MRI} are reported for both models Diff-in-exFast and model Diff-in, with Diff-in fitted only to high b-value images ($b > 1800 \text{ s/mm}^2$). In model Diff-in-exFast, the extra-cellular signal is modelled as negligible compared to the intra-cellular one (i.e., total signal dominated by intra-cellular water). Specimens are: *Control* (normal liver structures); NA1 and NA2 (normal appearing cases, i.e., normal liver structures despite subcutaneous biopsy implantation); Pat_{infl-3} (cases developing liver pathology following sub-cutaneous biopsy implantation, consisting of necrosis and inflammation). aCS_{histo} , always considerably lower than vCS_{histo} , was included to highlight the impact of the largest cells in the computation of statistics based on weighting by cell volume (vCS_{histo}).

]	Histology		Standard diffusion metrics		Diff-in-exFast model			Diff-in model at high b		
Specimen	F_{histo}	aCS _{histo} [µm]	vCS _{histo} [µm]	CD _{histo} /10 ² [cell/mm ²]	ADC [μ m ² /ms]	K	F_{MRI}	v <i>CSmri</i> [µm]	CD _{MRI} /10 ⁵ [cell/mm ³]	F_{MRI}	v <i>CS_{MRI}</i> [µm]	CD _{MRI} /10 ⁵ [cell/mm ³]
Control	0.75	21.63	27.1	3.2	1.50	0.33	0.60	33.2	0.38	0.56	36.5	0.28
	(0.18)	(1.85)	(1.6)	(1.1)	(0.32)	(0.20)	(0.18)	(5.7)	(1.69)	(0.11)	(5.1)	(1.44)
NA1	0.59	23.97	27.8	2.1	1.61	0.10	0.66	30.5	0.69	0.54	32.2	0.45
	(0.25)	(3.05)	(3.2)	(1.1)	(0.37)	(0.15)	(0.25)	(8.4)	(2.18)	(0.16)	(7.5)	(1.68)
NA2	0.76	23.46	29.4	2.7	1.43	0.51	0.80	22.2	1.01	0.71	22.8	0.83
	(0.14)	(1.41)	(1.2)	(0.7)	(0.44)	(0.29)	(0.16)	(4.8)	(1.35)	(0.12)	(5.0)	(1.15)
Pat _{inf1}	0.80	15.73	20.8	6.7	0.58	0.98	0.83	13.4	4.20	0.77	12.4	4.86
	(0.20)	(2.18)	(2.7)	(2.2)	(0.41)	(0.49)	(0.13)	(3.1)	(2.22)	(0.14)	(3.0)	(2.27)
Pat _{inf2}	0.79	21.41	26.8	3.5	1.67	0.17	0.37	31.2	0.44	0.41	37.1	0.30
	(0.20)	(2.29)	(2.7)	(1.2)	(0.39)	(0.17)	(0.22)	(7.5)	(2.06)	(0.14)	(6.0)	(1.57)
Pat _{inf3}	0.70	20.95	27.6	3.1	1.57	0.43	0.63	23.6	1.27	0.59	24.2	0.97
	(0.27)	(1.75)	(1.7)	(1.3)	(0.62)	(0.31)	(0.23)	(8.8)	(2.62)	(0.20)	(8.0)	(2.01)
Patnec	0.52	19.10	25.9	3.4	1.49	0.31	0.61	28.2	0.58	0.54	31.6	0.42
	(0.25)	(3.33)	(2.8)	(2.3)	(0.44)	(0.22)	(0.23)	(6.6)	(1.93)	(0.16)	(6.7)	(1.66)

Table S5. Hazard ratios obtained from Cox regression models controlling for sex, age, and baseline tumour volume.

The table reports the Hazard Ratios (HR) for different MRI metrics, with relative 95% confidence interval and p-value, estimated through Cox proportional hazard regressions. The models assessed the dependence of the probability of progression on the baseline mean value of MRI metrics within liver tumours, accounting for sex, age and tumour volume. Results are shown for standard diffusion metrics (apparent diffusion and excess kurtosis coefficients, *ADC* and *K*), for the vascular signal fraction f_v , for metrics from model *Diffin-exFast* (intra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$, extra-cellular fraction *F*, volume-weighted cell size *vCS*, cell density per unit volume *CD*, intrinsic intra-cellular cytosolic diffusivity $D_{0,I}$) fitted at high b-value ($b > 900 \text{ s/mm}^2$). Grey shadowing highlights HRs whose p-value is ≤ 0.05 .

HR of		HR of	HR of	HR of tumour							
	MRI metric	male sex	age	volume							
Standard diffusion MRI metrics											
ADC	1.00 (0.67;	0.71 (0.32;	0.97 (0.94;	0.32 (0.06;							
	1.49; $p = 1.00$	1.55; $p = 0.39$	(0.99); p = 0.02	1.70); $p = 0.18$							
K	1.36 (0.94;	0.64 (0.29;	0.97 (0.94;	0.35 (0.08;							
	1.97); <i>p</i> = 0.11	1.41; $p = 0.27$	1.00); p = 0.02	1.54); $p = 0.17$							
Other met	rics (from vascul	ar vs non-vascul	ar fitting initialis	ation step)							
f_{ν}	1.16 (0.79;	0.77 (0.35;	0.96 (0.93;	0.34 (0.17;							
	1.71); $p = 0.44$	1.68); $p = 0.51$	(0.99); p = 0.01	2.56); <i>p</i> = 0.17							
	Metrics from	m MRI model <i>Di</i>	ff-in-exFast								
F	0.87 (0.61;	0.78 (0.35;	0.97 (0.94;	0.31 (0.06;							
	1.26); $p = 0.46$	1.72); $p = 0.54$	1.00); p = 0.02	1.58); <i>p</i> = 0.16							
vCS	0.70 (0.44;	0.78 (0.36;	0.97 (0.94;	0.35 (0.08;							
	1.12); $p = 0.14$	1.68); $p = 0.53$	(0.99); p = 0.02	1.46); $p = 0.15$							
CD	1.53 (1.00;	0.63 (0.29;	0.96 (0.93;	0.32 (0.06;							
	(2.34); p = 0.05	1.38); <i>p</i> = 0.25	(0.99); p = 0.01	1.81); $p = 0.20$							
$D_{0,I}$	1.45 (0.98;	0.68 (0.31;	0.96 (0.93;	0.36 (0.09;							
- ,	2.14); <i>p</i> = 0.06	1.47); <i>p</i> = 0.33	(0.99); p = 0.01	1.35); <i>p</i> = 0.13							
$D_{E,\infty}$	1.41 (0.97;	0.69 (0.32;	0.96 (0.94;	0.40 (0.13;							
_,	2.05; $p = 0.07$	1.48); $p = 0.34$	(0.99); p = 0.01	1.26); <i>p</i> = 0.12							
Metri	cs from MRI mo	del Diff-in fitted	to high b-value in	mages							
F	0.79 (0.54;	0.80 (0.36;	0.97 (0.94;	0.33 (0.07;							
	1.17); <i>p</i> = 0.24	1.74); <i>p</i> = 0.57	(0.99); p = 0.02	1.49); <i>p</i> = 0.15							
vCS	0.59 (0.37;	0.66 (0.30;	0.96 (0.94;	0.40 (0.12;							
	(0.93); p = 0.02	1.43; $p = 0.29$	(0.99); p = 0.01	1.37); $p = 0.14$							
CD	1.65 (1.12;	0.61 (0.28;	0.96 (0.93;	0.36 (0.09;							
	(2.44); p = 0.01	1.35; $p = 0.22$	(0.99); p = 0.01	1.52); <i>p</i> = 0.17							
$D_{0,I}$	1.28 (0.82;	0.67 (0.31;	0.96 (0.94;	0.37 (0.09;							
- , , , , , , , , , , , , , , , , , , ,	1.98); $p = 0.28$	1.45; $p = 0.31$	(0.99); p = 0.01	1.48; $p = 0.16$							